EISAI CO., LTD.
AND
CONSOLIDATED SUBSIDIARIES
QUARTERLY FINANCIAL REPORT RELEASE

FOR IMMEDIATE RELEASE
January 30, 2009

Eisai Co., Ltd. hereby announces consolidated financial results for the Third Quarter of the fiscal year ending March 31, 2009.

- Eisai Co., Ltd. is listed on the First Section of the Tokyo Stock Exchange and the Osaka Securities Exchange.

- Securities Code Number: 4523

- Representative of corporation: Haruo Naito
  Director, President and CEO

- Inquiries should be directed to: Akira Fujiyoshi
  Vice President
  Corporate Communications

  4-6-10 Koishikawa, Bunkyo-ku
  Tokyo 112-8088, Japan
  Phone: ＋81-3-3817-5120
  URL http://www.eisai.co.jp/index-e.html

Expected date of Quarterly Financial Report submission: February 13, 2009

Note: For additional specific information, please refer to the official Japanese-language version of this release. This non-official English translation is provided as a courtesy only.

1. CONSOLIDATED QUARTERLY FINANCIAL RESULTS
Nine Months To December 31, 2008

1) RESULTS OF OPERATIONS

Period	Net Sales	Percent Change	Operating Income	Percent Change	Ordinary Income	Percent Change
April 1, 2008- Dec. 31, 2008	¥598,695 mil.	-%	¥73,416 mil.	-%	¥66,391 mil.	-%
April 1, 2007- Dec. 31, 2007	¥559,553 mil.	11.7%	¥92,540 mil.	10.4%	¥96,275 mil.	9.7%

Period	Net Income	Percent Change	Basic Earnings per Share	Diluted Earnings per Share
April 1, 2008- Dec. 31, 2008	¥39,171 mil.	-%	¥137.49	¥137.44
April 1, 2007- Dec. 31, 2007	¥63,514 mil.	13.7%	¥223.35	¥223.12

Note: Percentage Increase (decrease) reflects changes in comparison with the corresponding period of the previous year.

2) FINANCIAL POSITION

Period End	Total Assets	Equity	Shareholders' Equity Ratio	Book-value per share
Dec. 31, 2008	¥1,097,050 mil.	¥399,857 mil.	36.0%	¥1,386.58
March. 31, 2008	¥1,123,939 mil.	¥453,791 mil.	39.9%	¥1,575.49

Reference: Shareholders' Equity = Equity - Minority interests - Stock acquisition rights:

- As of December 31, 2008: ¥395,043 million
- As of March 31, 2008: ¥448,860 million

2. DIVIDEND CONDITION

	Dividend per share				
(Record Date)	First quarter end	Second quarter end	Third quarter end	Fiscal year end	Annual Total
March 31, 2008	-	¥65.00	-	¥65.00	¥130.00
March 31, 2009	-	¥70.00	-		
March 31, 2009 (Forecast)				¥70.00	¥140.00

Note: Revisions to dividend forecast in the quarter: None

3. CONSOLIDATED FINANCIAL FORECAST FOR THE FISCAL YEAR ENDING MARCH 31, 2009

Period	Net Sales	Operating Income	Ordinary Income	Net Income	Basic Earnings per Share
Full Year	¥780,000 mil. 6.2%	¥94,500 mil. 432.4%	¥82,500 mil. 337.7%	¥46,000 mil. - %	¥161.46

Note 1: Percentage Increase (decrease) reflects changes in comparison with the corresponding period of the previous year.

Note 2: Consolidated financial forecast has been revised. (Non-consolidated financial forecast has also been revised accordingly.)

4. OTHER

1) There were no transfers of important subsidiaries (transfers of specific subsidiaries* accompanied with a change in scope of consolidation) during the period.

*Subsidiaries that meet the following criteria:
1. The subsidiary's sales or purchases from the parent company represent 10% or more of the sales or purchases of the parent company.
2. The subsidiary's net assets are 30% or more than the net assets of the parent company
3. The amount of common stock is 10% or more than that of the parent company

2) Simplified accounting treatment: Applied
Accounting treatment specific to the preparation of quarterly financial statements: Not applied.

Note: For details, please refer to "5. Other " in "Qualitative Information / Financial Statements" on pages 19~22.

3) Change in accounting rules, procedures and representation method in connection with the preparation of consolidated financial statements:
(1) Changes in accounting principles: Yes
(2) Changes other than (1): Yes

Note: For details, please refer to "5. Other " in "Qualitative Information / Financial Statements" on pages 19~22.

4) Number of shares issued and outstanding (common stock):
(1) Number of shares issued and outstanding at the end of period (including treasury stock)
- Nine-month period ended December 31, 2008: 296,566,949 shares
- Fiscal year ended March 31, 2008: 296,566,949 shares

(2) Number of shares of treasury stock at the end of period
- Nine-month period ended December 31, 2008: 11,662,792 shares
- Fiscal year ended March 31, 2008: 11,665,319 shares

(3) Average number of shares of treasury stock during the period
- Nine-month period ended December 31, 2008: 284,903,710 shares
- Nine-month period ended December 31, 2007: 284,365,124 shares

Notes and special instructions for the use of financial forecast provided in this document
1: Details for the figures and assumptions for forecast are provided on pages 16 and 17.
2: Effective from this fiscal year, ASBJ Statement No.12, "Accounting Standard for Quarterly Financial Reporting," and ASBJ Guidance No.14, "Guidance on Accounting Standard for Quarterly Financial Reporting," have been applied. In addition, pursuant to Cabinet order No. 50、"Revised version of Regulation concerning terminology, forms and methods of preparation of consolidated financial statements" under supplemental provision of Article 7, paragraph 1, provisory clause of item. 5 issued on August 7, 2008, quarterly consolidated financial statements were prepared in accordance with the "Regulation Concerning Terminology, Forms and Methods of Preparation of Quarterly Consolidated Financial Statements."
3: As a result of applying new accounting principles as stated above, this summary information does not include percentage changes from the corresponding period (3Q) of the previous year.

[Qualitative Information / Financial Statements]

Index and money amount comparisons to the previous period's figures are stated for reference in this document. Differences arising from changes to accounting treatment between the current nine-month period and the previous nine-month period are indicated in "5. Other" on pages 19 to 22.

1. Overview of Consolidated Operating Results

1) Operating Results (April 1 - December 31, 2008)

[Sales and income]

- The Company achieved the following **consolidated financial results** for the nine months ended December 31, 2008:

Net sales:	¥598,695 million	(7.0% increase year-on-year)
Operating income:	¥73,416 million	(20.7% decrease year-on-year)
Ordinary income:	¥66,391 million	(31.0% decrease year-on-year)
Net income:	¥39,171 million	(38.3% decrease year-on-year)

- **Sales of *Aricept***, an Alzheimer's disease treatment, expanded to ¥228,960 million, up 4.5% year-on-year. **Sales of *Pariet*** (US brand name: *Aciphex*), a proton pump inhibitor, however, decreased to ¥123,178 million, down 12.0%. **Sales of *Aloxi***, an antiemetic agent, were ¥27,984 million, and **sales of *Dacogen***, a DNA methyltransferase inhibitor, came to ¥12,581 million. On a geographical segment basis, North America and China posted continuous steady sales increases, and sales in Japan stayed strong.
- **Operating income**, **ordinary income** and **net income** dropped as a result of amortization of goodwill associated with the acquisition of MGI PHARMA, INC., which was completed in the previous period, and proactive investment in R&D activities.
- Consequently, **net income per share** came to ¥137.49 (down ¥85.87 year-on-year).

[Adjusted basis]

- **Consolidated operating results on an adjusted basis**, in which the figures specific for the accounting treatment related to the acquisition of MGI PHARMA, INC. in the previous period (non-cash items) were deducted from the current GAAP basis figures in order to depict actual business performance, are as follows:

Net sales:	¥598,695 million	(7.0% increase year-on-year)
Operating income:	¥95,487 million	(3.2% increase year-on-year)

Ordinary income:	¥88,463 million (8.1% decrease year-on-year)
Net income:	¥55,901 million (12.0% decrease year-on-year)

- Increased interest expenses and foreign exchange losses as well as loss on devaluation of investment securities resulted in a decline in ordinary income and net income on an adjusted basis.
- Consequently, net income per share on an adjusted basis came to ¥196.21 (down ¥27.14 year-on-year).

[Cash generating ability]

Cash income* is the total amount of cash available for investment in future growth, business development, dividend payment and repayment of borrowings and it represents the company's ability to generate cash. In this financial reporting, cash income is stated as a measure to examine the company's growth potential and strategies.

Cash income for the period was ¥90,014 million (up 2.7% year-on-year).

*Cash income = Net income (loss) + depreciation of PP&E and amortization of intangible assets + in-process R&D expenses + amortization of goodwill + loss on impairment (including loss on devaluation of investment securities)

[Performance by segment]

(Sales for each segment are those to external customers.)

(1) Performance by operating segment

<Pharmaceuticals segment>

- **Sales of pharmaceuticals** increased as a result of the continued strong sales of *Aricept* as well as the contribution of MGI PHARMA's two main products, *Aloxi* and *Dacogen*.
- **Pharmaceutical sales** increased 7.4% year-on-year to ¥582,786 million, while operating income decreased 19.6% year-on-year to ¥75,648 million, due to the amortization of goodwill associated with the acquisition of MGI PHARMA, INC. and proactive investment in R&D activities.

<Other>

- **Sales of food additives, chemicals and machinery** decreased 7.2% year-on-year to ¥15,908 million, and operating income also decreased 9.7% year-on-year to ¥1,376 million.

(2) Performance by geographical segments

<Japan>

- **Sales in Japan** amounted to ¥258,478 million, up 4.8% from the previous year, while operating income decreased 15.4% to ¥60,925 million due to proactive investment in R&D activities.
- Among prescription drugs, **sales of *Aricept*** increased to ¥60,986 million, up 24.5%, and sales of ***Pariet*** increased to ¥35,037 million, up 18.7% from the previous year.
- "**HUMIRA subcutaneous injection 40mg Syringe 0.8mL,"** a fully human monoclonal anti-TNFα antibody, was launched in June 2008 for the treatment of rheumatoid arthritis.

<North America>

- **Sales in North America** increased 10.8% year-on-year to ¥277,195 million. Operating income decreased 59.5% to ¥6,878 million. Operating income on an adjusted basis, calculated by deducting the figures specific for the accounting treatment of acquisitions (non-cash items) from the current GAAP basis figures, was ¥28,950 million (up 70.6% year-on-year).
- **Sales of *Aricept*** increased 1.2% to ¥139,098 million, and **sales of *Aciphex*** decreased 23.1% to ¥76,483 million. (Sales on a dollar-denominated basis increased 15.4% for *Aricept*, while sales for *Aciphex* decreased 12.3%) **Sales of *Aloxi*** were ¥27,984 million, and **sales of *Dacogen*** were ¥12,581 million.
- **Promotional activities for *Aloxi injection 0.075 mg*** for the prevention of postoperative nausea and vomiting (PONV) were launched in July 2008.

<Europe>

- **Sales in Europe** decreased 2.4% to ¥40,647 million, and operating income increased 81.0% to ¥2,675 million.
- **Sales of *Aricept*** decreased 12.7% to ¥22,971 million, and sales of ***Pariet*** increased 15.1% to ¥7,539 million.

<China>

- **Sales in China** increased 21.1% to ¥8,591 million, and operating income increased 25.1% to ¥1,729 million.
- **Sales of *Aricept*** increased 5.2% to ¥692 million, and sales of ***Pariet*** decreased 0.3% to ¥516 million

<Asia and Others (excluding China)>

- **Sales in Asia and other regions** decreased 2.0% to ¥13,782 million, and operating income increased 7.0% to ¥3,126 million.
- **Sales of *Aricept*** were ¥5,210 million, down 7.0%, and ***Pariet*** sales were

¥3,600 million, down 6.5%.

<Overseas total>

- **Total overseas sales** excluding Japan grew to ¥340,216 million, up 8.7% from the previous year, and accounted for 56.8% of the Company's total net sales, up 0.9 percentage points year-on-year.

2) Third Quarter Financial Highlights (October 1- December 31, 2008)

- **Consolidated net sales** during the quarter amounted to ¥199,866 million, an increase of 1.6% from the previous year.
- **Net sales of *Aricept*** came to ¥76,383 million, down 2.3% year-on-year, out of which ¥22,732 million was attributed to Japan, where sales rose by 20.0%, and ¥45,833 million was attributed to the U.S., where sales declined by 4.6% (but rose by 12.0% on a U.S. dollar-denominated basis).

  Sales of *Pariet/Aciphex* totaled ¥40,623 million, a 14.8% decrease year-on-year, out of which ¥13,356 million was attributed to Japan, where sales rose by 18.8%, and ¥23,605 million was attributed to the U.S., where sales declined by 28.6% (a decrease of 15.9% on a U.S. dollar-denominated basis).

  Sales of *Aloxi* were ¥9,063 million, and **sales of *Dacogen*** came to ¥3,915 million.
- **With respect to sales to external customers** in each geographical area, sales in Japan, North America, and China expanded by 3.4%, 4.4% and 8.1% respectively, but sales in Europe and "Asia and other (excluding China)" decreased by 19.3% and 23.0% respectively.
- **R&D expenses** came to ¥38,878 million, up 8.8% from the previous period, and **Selling, general and administrative expenses** amounted to ¥94,480 million, down 2.2%. **Cost of goods sold** went up 36.9%, to ¥39,635 million, and the cost of sales ratio increased by 5.1 percentage points to 19.8%.
- **Operating income** was ¥26,871 million, down 24.3% year-on-year, ordinary income was ¥22,781 million, down 37.9%, and net income was ¥10,458 million, down 56.7%. Net income per share decreased by ¥48.15, to ¥36.71.

  Operating income, ordinary income and net income on an adjusted basis were ¥33,570 million (down 5.4% year-on-year), ¥29,480 million (down 19.7%) and ¥15,639 million (down 35.3%) respectively, while net income per share on an adjusted basis was ¥54.89 (down ¥29.96).
- **Net cash provided by operating activities** came to ¥1,628 million, down ¥8,494 million year-on-year. Income before income taxes amounted to ¥17,180 million, depreciation and amortization expenses were ¥11,885 million, trade receivables increased by ¥18,819 million, while income taxes paid totaled ¥18,855 million.

Net cash used in investing activities increased by ¥10,634 million to ¥19,830 million, out of which ¥7,524 million was used to purchase property, plant and equipment.

Net cash provided by financing activities amounted to ¥19,468 million, an increase of ¥18,157 million from the same period of the previous year.

3) Research & Development and Other Events

Status of Ongoing Research Projects

- **Anticancer agent E7389** (microtubule dynamics inhibitor) is being investigated for a breast cancer indication in a Phase III study in the U.S. and in Europe, and in a Phase II study in Japan. Phase II studies are ongoing for non-small cell lung cancer (the U.S.), prostate cancer (the U.S. and Europe), and sarcoma (Europe) indications.
- **AMPA receptor antagonist E2007** is being investigated with a focus on neuropathic pain and epilepsy indications. In the U.S. and Europe, a Phase III study for an epilepsy indication and a Phase II study for a neuropathic pain indication are ongoing. A Phase II study for an epilepsy indication has been initiated in Japan.
- **Endotoxin antagonist E5564** is being investigated in a Phase III study for the potential treatment of severe sepsis in Japan, the U.S. and Europe with a plan to submit applications simultaneously at these locations. The study is being conducted at multiple sites globally.
- **A new oral formulation of an anti-emetic agent *Aloxi*** (capsules) received approval for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in the U.S. in August 2008.
- In October 2008, the U.S. FDA approved an efficacy supplemental biologics license application (sBLA) for ***Ontak*** solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+). The FDA's action, following a priority review, marks the conversion of an accelerated approval indication to full approval. Separate sBLA, which was submitted for the potential treatment of patients with CTCL whose malignant cells did not test positive for the CD25 component of the IL-2 receptor (CD25-), received a complete response letter and was not approved. Eisai will continue to work with FDA to seek the approval.

- In November 2008, **antiepileptic drug *Banzel*** was approved by the U.S. FDA for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults. A complete response letter was issued for ***Banzel*** as an adjunctive treatment for partial-onset seizures with and without secondary generalization in adults and adolescents 12 years of age and older. Eisai will work with the FDA to determine the next appropriate steps.
- In December 2008, the U.S. FDA approved ***Lusedra*** Injection, an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The FDA has recommended that the agent be classified as a controlled substance. A final scheduling decision is expected from the U.S. Drug Enforcement Administration (DEA) after publishing a proposed rule in the Federal Register and allowing for public comment.
- A submission is in preparation for **the DNA hypomethylating agent *Dacogen*** for a five day dosing regimen for the treatment of myelodysplastic syndromes (MDS) in the U.S.
- A Phase II study of **anticancer agent E7080** (VEGF receptor tyrosine kinase inhibitor) for the indication of thyroid cancer has been initiated and is ongoing in the U.S.
- **Human monoclonal anti-TNFα antibody HUMIRA** was approved for the treatment of rheumatoid arthritis in Japan in April 2008. In addition, a Phase III study for examining effects against inhibition of structural damage of joints and a Phase II/III study for ulcerative colitis have been initiated in Japan.
- **Non-ionic contrast media *Iomeron* 350 and *Iomeron* 350 syringe** received additional approval for usage in dynamic computed tomography (dynamic CT) of the liver in Japan in May 2008. In addition, a higher volume of Iomeron 350 syringe (135 ml formulation) was approved.
- A Phase III study of **SEP-190 ($GABA_A$ receptor agonist)** has been initiated for an insomnia indication in Japan.
- **Gastroprokinetic agent *Gasmotin*** received approval for the treatment of gastrointestinal symptoms associated with functional dyspepsia in Thailand in September 2008. The agent has been filed for approval in Malaysia, Indonesia, and the Philippines. Submissions are being prepared for application in six other Asian countries including some ASEAN members.
- A liquid formulation of ***Aricept***, **the Alzheimer's disease treatment,** was

approved in the U.K. in October 2008.

- **Proton pump inhibitor *Pariet/Aciphex*** received approval for short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in adolescents (ages 12 and above) in the U.S. in June 2008. A Phase II/III study for additional dosage for reflux esophagitis has been initiated in Japan.
- **The anticancer agents MORAb-003** and **MORAb-009** (monoclonal antibodies) received orphan drug status from the European Commission in April 2008. Since June 2008, clinical sites for conducting the MORAb-009 Phase II study have been expanded to the European Union (EU).

Alliances & Agreements

- **Agreements were concluded with Eisai's diagnostic subsidiary Sanko Junyaku Co., Ltd., Roche Diagnostics K.K., Nihon Kohden Corporation, and F. Hoffmann-La Roche Ltd (Switzerland)** in April 2008 concerning the sale of CoaguChek XS and CoaguChek XS Plus for simple and quick PT-INR (Prothrombin Time - International Normalized Ratio) monitoring along with other related supplies. Under these agreements, effective June 2008, the sales rights of these products in Japan have been transferred from Roche Diagnostics and Nihon Kohden to Sanko Junyaku, with co-promotion rights retained by Eisai. Roche Diagnostics remains as a manufacturer (importer) of CoaguChek XS Series, and Nihon Kohden offers sales and technical support as the distributor.
- **Lion Corporation and Eisai Co., Ltd. signed an agreement granting Eisai exclusive marketing rights in Japan for Bufferin (ethical drug)** in May 2008. Prior to this action, Lion Corporation, Bristol-Myers K. K. (BMKK) and Eisai Co., Ltd. had agreed to change the distributor of Bufferin 81mg Tablets (antiplatelet drug), and Bufferin 330mg Tablets (antipyretic /analgesic/ antiphlogistic drug) from BMKK to Eisai starting July 1, 2008. The manufacturing and marketing rights of these products in Japan are owned by Lion.
- **GlaxoSmithKline K.K. and Eisai Co., Ltd. agreed to terminate their marketing alliance for the *Breathe Right*** nasal strips manufactured by GlaxoSmithKline group, effective May 31, 2008. The product had been marketed in Japan by Eisai. As a result, GlaxoSmithKline K.K. has taken over the marketing of the product in Japan as of June 1, 2008.
- **Eisai Co., Ltd. entered into a share transfer agreement with Terumo**

Corporation for the transfer of Eisai's interest (84.8% of total shares issued) in its consolidated subsidiary, Clinical Supply Co., Ltd., to Terumo Corporation in June 2008. The shares were transferred in June 2008 following the exectution of this agreement.

- **Eisai's U.S. subsidiary Morphotek, Inc. signed a license agreement with the National Cancer Institute (NCI)** for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers in June 2008. Morphotek will apply its proprietary MORPHODOMA antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer.
- **Eisai's subsidiary Eisai China Inc. entered into a license agreement in July 2008 with Hong-Kong-based Health Vision Enterprise Ltd., a sales subsidiary of the German company STADA Arzneimittel AG,** in which Eisai China Inc. was granted rights in China to sell and repackage of α-Lipon 300 STADA (generic name: α-lipoic acid), a treatment for diabetic neuropathic pain developed by STADA.
- **Morphotek, Inc. and Pivotal BioSciences, Inc. (U.S.) in July 2008 entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC (Liver-Expression Chemokine) platform technology** for the development of therapeutic monoclonal antibodies. The agreement will allow Morphotek to evaluate the LEC technology in-house and give the company the right to exercise an option for a license. Should Morphotek choose to exercise its option, Morphotek would obtain a worldwide license under Pivotal's LEC technology to develop new therapeutic products, and would retain responsibility for the commercialization of such products derived using the technology.
- **A license agreement was concluded with SymBio Pharmaceuticals Limited in August 2008** for the co-development and commercialization in Japan for bendamustine hydrochloride. Currently, SymBio is conducting a pivotal study in patients with low-grade non-Hodgkin's lymphoma prior to submission for approval.
- **Morphotek Inc. signed a sponsored research agreement with the University of Pennsylvania (U.S.)** in November 2008 to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors.
- **Morphotek, Inc. signed an evaluation agreement with the University**

Hospital Heidelberg (Germany) and its Technology Transfer Office in November 2008 to advance the company's efforts in the discovery and development of therapeutic antibodies in oncology. The agreement provides for a research grant to the University Hospital/National Center for Tumor Diseases and for use by Morphotek of biological materials to generate and validate therapeutic monoclonal antibodies to oncology targets selected by Morphotek.

- **Eisai completed an alliance agreement with TorreyPines Therapeutics, Inc. (U.S.)** in November 2008 for the discovery of genes associated with late onset Alzheimer's disease which had been effective since 2002. Following the completion, the companies signed a new agreement in which Eisai will purchase all research data and assets obtained from such research activities conducted by TorreyPines Therapeutics.

Other events

- **With respect to Eisai's patent infringement lawsuit against U.S. generic manufacturers concerning its proton pump inhibitor *Aciphex* (Product Name in Japan: *Pariet*)**, the United States Court of Appeals for the Federal Circuit affirmed both the United States District Court for the Southern District of New York's summary judgment ruling on the validity of Eisai's composition of matter patent and its ruling on the enforceability of the composition of matter patent in July 2008.

2. Consolidated Financial Position

[Assets, liabilities and equity]

- **Total assets** at the end of the period decreased by ¥26,888 million year-on-year to ¥1,097,050 million. The decrease resulted primarily from exchange rate fluctuations, which caused loss in assets of overseas subsidiaries in yen equivalents, leading to the decrease in Intangible assets and short-term investments. On the other hand, increases were reported in securities, notes, and accounts receivables-trade.
- **Total liabilities** increased by ¥27,044 million year-on-year to ¥697,192 million.
- **Total equity** decreased by ¥53,933 million year-on-year to ¥399,857 million, and the shareholders' equity ratio* decreased by 3.9 percentage points year-on-year to 36.0%.
  *(Equity – Minority interests – Stock acquisition rights) / Total assets

[Financing]

- Short-term borrowings at the end of the third quarter decreased by ¥317,819 million, to ¥45,000 million, straight bonds increased by ¥119,761 million, to ¥120,591 million, and long-term borrowings increased by ¥223,721 million, to ¥273,721 million.
- The Company issued ¥120 billion worth of unsecured straight bonds in Japan in June 2008 and received long-term loans totaling ¥160 billion from banks and insurance companies in July and August 2008.
- The short-term borrowings Eisai used to finance the acquisition of MGI PHARMA, INC. in the previous fiscal year have been refinanced to straight bonds and long-term borrowings as of August 2008.
- The company is promoting a financial strategy that seeks to achieve and maintain a credit rating that is higher than its current rating, while securing financial flexibility, stability and soundness.
- Moody's Investors Service and Rating and Investment Information, Inc. have assigned ratings of "A" and "AA-" to Eisai Co., Ltd.'s long-term liabilities.

[Cash Flow]

- **Net cash provided by operating activities** for the nine months ended December 31, 2008 came to ¥70,965 million, up ¥19,112 million from the previous year. Income before income taxes amounted to ¥60,787 million, depreciation and amortization expenses were ¥36,785 million, trade

receivables increased to ¥27,608 million, and income taxes paid totaled ¥35,880 million.

- **Net cash used in investing activities** amounted to ¥36,839 million, a decrease of ¥24,981 million, out of which ¥27,428 million was used to purchase property, plant and equipment.
- **Net cash used in financing activities** amounted to ¥6,073 million, a decrease of ¥11,391 million from the same period of the previous year, out of which ¥38,462 million was paid as dividends.
- As a result of such operating, investing and financing activities, **cash and cash equivalents** at the end of the period came to ¥130,307 million, up ¥10,357 million from the end of the previous period.

3. Basic policy on profit appropriation and forecasted year-end dividend for the fiscal year ending March 31, 2009

Eisai is a company with a committee system and, to facilitate a flexible dividend policy, as specified in the Company's Articles of Incorporation, dividend payments are to be determined by a resolution of the Board of Directors.
Eisai is devoted to providing sustainable and stable dividends based on the consolidated financial performance along with the Dividend on Equity ratio (DOE). DOE is considered a suitable and well-balanced index for shareholder return as it encompasses both the Dividend Payout Ratio (DPR), which measures the extent to which profits are distributed to shareholders in the form of dividends, and Return on Equity (ROE), which measures how effectively the company uses the money invested by shareholders to generate profits.

Eisai intends to pay a year-end dividend of ¥70 per share to shareholders, up ¥5 from the previous year. With an interim dividend of ¥70 per share paid at the end of the second quarter, the total dividend for the year will be ¥140 per share, up ¥10 from the previous year. In this context, DOE is anticipated to be 9.4%.

Acquisition of treasury stock will be carried out flexibly on a timely basis.

4. Outlook for the Fiscal Year Ending March 31, 2009

[Consolidated Forecast]

- The full-year consolidated forecast announced in October 2008 has been revised as follows:

	Revised Forecast		Forecast in October '08		Increase/ (Decrease)	Rate of Changes
	(A)	y/y (%)	(B)	y/y (%)	(A-B)	
Net sales	¥780,000 mil.	+6.2	¥806,000 mil.	+9.8	(¥26,000 mil.)	(3.2%)
Operating income	¥94,500 mil.	+432.4	¥94,000 mil.	+429.6	¥500 mil.	0.5%
Ordinary income	¥82,500 mil.	+337.7	¥86,500 mil.	+358.9	(¥4,000 mil.)	(4.6%)
Net income	¥46,000 mil.	-	¥56,500 mil.	-	(¥10,500 mil.)	(18.6%)

Notes:

*Forecasted Annual Earnings per share (full year): ¥161.46

(Assumptions for the 4th quarter) US$1=¥90, 1 Euro =¥120, 1 Sterling Pound =¥125

*y/y : Percentage change compared with the previous year

*% : Percentage increase (decrease) between the revised forecast and the previous forecast

<Net Sales>

- In spite of the continued strong sales are anticipated for *Aricept* and anti-cancer agents, the forecast for net sales is decreased by ¥26,000 million below the previous forecast, to ¥780,000 million, due to the appreciation of the yen.
- The sales for our two main products are anticipated to decline. The sales for *Aricept* are decreased by ¥11,000 million below the previous forecast to ¥303,000 million, and those for *Pariet/Aciphex* is decreased by ¥4,000 million, to ¥157,000 million.

<Income>

The forecast for income on an adjusted basis are as follows:

- The forecast for operating income remains unchanged from the previous forecast of ¥122,500 million, supported by the potential decreases in operating expenses and SG&A expenses, offsetting the decline in sales resulting from strong yen.
- The forecast for ordinary income is decreased by ¥4,500 million below the previous forecast, to ¥110,500 million, affected from the loss on foreign exchanges.
- The forecast for net income is decreased by ¥11,300 million below the previous forecast, to ¥67,000 million, due to the decline in short-term investments caused by flogging stock prices.

Based on the forecast on an adjusted basis as stated above, the GAAP-based forecast has been revised as follows:

- The forecast for GAAP-based operating income is increased by ¥500 million above the previous forecast, to ¥94,500 million, due to the appreciation of the yen, which will result in lower expenses related to the acquisition of MGI PHARMA, INC.
- The forecast for GAAP-based ordinary income is decreased by ¥4,000 million below the previous forecast, to ¥82,500 million, and the forecast for net income is decreased by ¥10,500 million, to ¥46,000 million.
- We also envision proactive investment in R&D activities and in other efforts to promote sustainable future growth, while promoting efforts to achieve improvements in the cost-of-sales ratio and the efficiency of managerial resources

(Reference)
[Non-consolidated Forecast]

- The full-year non-consolidated forecast announced in October 2008 has been revised as follows:

	Revised Forecast		Forecast in October '08		Increase/ (Decrease)	Rate of Changes
	(A)	y/y (%)	(B)	y/y (%)	(A-B)	
Net sales	¥401,000 mil.	+3.0	¥405,000 mil.	+4.1	(¥4,000 mil.)	(1.0%)
Operating income	¥67,500 mil.	-7.7	¥70,000 mil.	-4.2	(¥2,500 mil.)	(3.6%)
Ordinary income	¥57,500 mil.	-19.1	¥62,500 mil.	-12.0	(¥5,000 mil.)	(8.0%)
Net income	¥36,000 mil.	-21.7	¥46,500 mil.	+1.1	(¥10,500 mil.)	(22.6%)

Notes:
*Forecasted Annual Earnings per share (full year): ¥126.36
(Assumptions for the 4th quarter) US$1=¥90, 1 Euro =¥120, 1 Sterling Pound =¥125
*y/y : Percentage change compared with the previous year
*% : Percentage increase (decrease) between the revised forecast and the previous forecast

[Forecast and risk factors]

- Materials and information provided in this financial disclosure may contain "forward-looking statements" based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general

industry and market conditions, and domestic and international economic conditions, such as interest rate and currency exchange fluctuations.

- Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on investment decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to dependence on specific products, risks related to strategic alliances with partners, risks related to the acquisition of MGI PHARMA, INC., healthcare cost-containment measures, competition from and litigation with manufacturers of generic drugs, intellectual property, possible incidence of adverse events, compliance with laws and regulations, litigations, closure or shutdown of factories, safety issues of raw materials used, outsourcing-related risks, environmental issues, IT security/information management, conditions of financial markets, foreign exchange fluctuations, and the development of an internal control system.

  Please refer to “Risk Factors” in the Annual Securities Report for details.

5. Other

1) Simplified accounting treatment and specific accounting treatment in the quarterly financial statements

(1) Simplified accounting treatment

a) The balance of inventories as of September 30, 2008 is calculated based on the physical counts of inventories as of the prior fiscal year end and the proper records of entering and / or dispatching of such inventories during the third quarter.

(2) Accounting treatment specific to the preparation of quarterly financial statements

Not applied.

2) Changes in Accounting Policies, Practices and Presentation Methods in Quarterly Consolidated Financial Reports

(1) Changes reflecting application of new accounting standards

a) Effective from this fiscal year, ASBJ Statement No.12, “Accounting Standard for Quarterly Financial Reporting,” and ASBJ Guidance No.14, “Guidance on Accounting Standard for Quarterly Financial Reporting,” have been applied. In addition, pursuant to Cabinet order No. 50、”Revised version of Regulation concerning terminology, forms and methods of preparation of consolidated financial statements” under supplemental provision of Article 7, paragraph 1, provisory clause of item. 5 issued on August 7, 2008, quarterly consolidated financial statements were prepared in accordance with the “Regulation Concerning Terminology, Forms and Methods of Preparation of Quarterly Consolidated Financial Statements.”

b) Prior to April 1, 2008, inventories held for sale in the ordinary course of business were stated at cost, determined by the cost averaging method. The Accounting Standard Board of Japan (ASBJ) issued ASBJ Statement No. 9, dated July 5, 2006, “Accounting Standard for Measurement of Inventories,” which is effective for fiscal years beginning on or after April 1, 2008, which requires that inventories held for sale in the ordinary course of business be measured at the lower of cost or net selling value. The Company adopted the new accounting standard for measurement of inventories from the first quarter for the fiscal year ending March 31, 2009. The effect of adoption of this accounting standard on operating income,

ordinary income, and income before income tax for the current nine-month period was not material.

c) Effective from this fiscal year, the Company applied the new Practical Issues Task Force (PITF), "Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statements (ASBJ PITF No. 18, May 17, 2006)," and accordingly made any necessary modifications including amortization of goodwill to its consolidated financial statements. The effect of adoption of this standard was to decrease operating income, and ordinary income and income before income taxes and minority interests for the current nine-month period by ¥7,216 million, ¥7,101 million, and ¥7,101 million respectively. The effect of this change on segment information is stated in the relevant sections.

Goodwill purchased by an overseas subsidiary is amortized on a straight-line basis over 20 years.

(2) Changes other than (1)

a) Previously, Eisai and its domestic subsidiaries had amortized their property, plant and equipment by the declining balance method, but from this fiscal year, the Company uses the straight line method, which has been used by Eisai's overseas subsidiaries.

The Company has decided to apply the straight line method mainly for the three reasons stated below to ensure uniformity in the application of its accounting treatment and to more appropriately measure periodic income.

i) As a result of carrying out the Company's midterm plan started in April 2006, the balance of property, plant and equipment attributable to subsidiaries outside of Japan is expected to get proportionately larger in the future, and global business operations are becoming increasingly important. In this context, the Company found it necessary to ensure consistency with its foreign subsidiaries in its accounting treatment for depreciation and amortization, taking into consideration International Financial Reporting Standards and U.S. GAAP.

ii) As Eisai's product lines can expect to generate long-term and stable profits, the straight line method is a more suitable way to reflect the allocation of depreciation expenses over a stream of earnings.

iii) Property, plant and equipment held by the Company and its domestic subsidiaries generally are subject to steady operation over their expected lifetime, and repairs and maintenance of facilities are regularly planned and carried out. In this context, repairs and maintenance expenses are expected to remain regular, with few severe fluctuations.

The effect of adoption of this change from the declining balance method to the straight line method on the results of the current nine-month period was to decrease consolidated depreciation expenses by ¥1,873 million and increase operating income, ordinary income, and income before income tax and minority interests by ¥1,270 million respectively.
With the start of the change of depreciation method, the Company and its subsidiaries have introduced a unified treatment on residual values in which depreciable assets are to be depreciated to 1 yen (the defined residual value) at the end of their useful life.
The effect of adoption of this change on the results of the current nine-month period was to increase depreciation expenses by ¥1,507 million and decrease operating income, ordinary income, and income before income tax and minority interests by ¥1,006 million.

The aggregated effect of the change to the straight line method and the change in residual value as stated above on the results of the current nine-month period was to decrease amortization costs by ¥366 million and increase operating income, ordinary income, and income before income tax and minority interests by ¥264 million respectively. The effect of this change on segment information is stated in the relevant sections.

b) Effective from this fiscal year, Eisai has implemented early adoption of the "Accounting Standard for Lease Transactions (Statement No.13, amended on March 30, 2007)" and the "Guidance on Accounting Standard for Lease Transactions (Guidance No.16, amended on March 30, 2007)," which requires that all finance lease transactions shall be capitalized, although finance leases in which there is no transfer of ownership were accounted for as operating leases under the former accounting standard for lease transactions.

Under the new accounting standard, finance lease transactions in which there is no transfer of ownership are amortized by the straight-line method over the term of the lease, with a residual value of zero.

The effect of adoption on the results of the current nine-month period of this accounting standard was not material.

[Additional Information]

(1) Significant Hedge accounting

The Company has entered into interest rate swaps agreements since the second quarter for the fiscal year ending March 31, 2009 as a means of managing its interest rate exposure on a portion of its long-term borrowings. The accounting treatment of derivative financial Instruments under hedge accounting is as follows:

a) Hedging accounting method

The Company uses the deferred hedge method for its hedging accounting.

Preferential procedures have been employed when the interest rate swaps meet specific matching criteria for such procedures.

b) Hedging instruments and hedged items

Hedging instruments: Interest rate swaps

Hedged items: Long-term borrowings

c) Hedging policies

The Company uses derivative financial instruments for hedging its long-term borrowings to manage its exposure to fluctuations in interest rates in accordance with internal policies which regulate the authorization and credit limit amount, and interest rate swaps are utilized by the Company to reduce interest rate risks.

d) Method for evaluation of effectiveness of hedging instruments

The Company evaluates the correlation and hedging effectiveness between the hedging instruments and the hedged items at the end of every quarterly period.

The Company is allowed to omit this evaluation for Interest rate swaps which qualify for hedging accounting and meet specific matching criteria.

6. CONSOLIDATED FINANCIAL STATEMENTS

Effective from this fiscal year, ASBJ Statement No.12, "Accounting Standard for Quarterly Financial Reporting," and ASBJ Guidance No.14, "Guidance on Accounting Standard for Quarterly Financial Reporting," have been applied. In addition, pursuant to Cabinet order No. 50、"Revised version of Regulation concerning terminology, forms and methods of preparation of consolidated financial statements" under supplemental provision of Article 7, paragraph 1, provisory clause of item. 5 issued on August 7, 2008, quarterly consolidated financial statements were prepared in accordance with the "Regulation Concerning Terminology, Forms and Methods of Preparation of Quarterly Consolidated Financial Statements."

1) CONSOLIDATED BALANCE SHEETS

(millions of yen)

	December 31, 2008	March 31, 2008
ASSETS		
Current assets:		
Cash and cash in banks	58,004	68,593
Notes and accounts receivable-trade	190,561	172,143
Short-term investments	87,051	56,287
Finished goods and merchandise	28,438	32,070
Work-in process	14,846	12,961
Raw materials and supplies	12,774	13,059
Deferred tax assets	33,591	35,399
Other	16,325	25,361
Allowance for doubtful receivables	(305)	(308)
Total current assets	441,290	415,568
Non-current assets:		
Property, plant and equipment		
Buildings and structures-net	68,139	70,750
Other-net	81,148	76,332
Total property, plant and equipment-net	149,288	147,083
Intangible assets		
Goodwill	159,089	178,671
Sales rights	135,765	164,247
Core technology	53,536	61,346
Other	12,078	13,424
Total intangible assets	360,469	417,690
Investments and other assets		
Investment securities	66,934	89,544
Deferred tax assets	65,520	43,650
Other	14,010	10,994
Allowance for doubtful accounts	(462)	(591)
Total investments and other assets	146,002	143,597
Total non-current assets	655,760	708,370
Total assets	1,097,050	1,123,939

(millions of yen)

	December 31, 2008	March 31, 2008
LIABILITIES		
Current liabilities:		
Notes and accounts payable-trade	18,131	18,307
Short-term borrowings	45,000	362,819
Accounts payable-other	60,801	59,932
Accrued expenses	48,498	56,738
Income taxes payable	15,437	16,088
Reserve for sales rebates	27,698	23,324
Other reserves	552	437
Other	11,215	5,542
Total current liabilities	227,335	543,191
Long-term liabilities:		
Bonds and debentures	120,591	830
Long-term borrowings	273,721	50,000
Deferred tax liabilities	32,278	40,249
Liability for retirement benefits	22,452	24,104
Retirement allowances for directors	2,253	2,140
Negative goodwill	1,218	1,461
Other	17,341	8,170
Total long-term liabilities	469,857	126,956
Total liabilities	697,192	670,147
Equity		
Owners' Equity		
Common stock	44,985	44,985
Capital surplus	56,954	56,966
Retained earnings	414,797	415,961
Treasury stock	(39,690)	(39,694)
Total Owners' Equity	477,047	478,219
Net unrealized gain (loss) and translation adjustments:		
Net unrealized gain (loss) on available-for-sale securities	3,400	9,509
Deferred gain (loss) on derivatives under hedge accounting	(686)	—
Foreign currency translation adjustments	(84,716)	(38,868)
Total net unrealized gain (loss) and translation adjustments	(82,003)	(29,359)
Stock acquisition rights	594	556
Minority Interests	4,220	4,374
Total equity	399,857	453,791
Total liabilities and Equity	1,097,050	1,123,939

2) CONSOLIDATED STATEMENT OF INCOME

(millions of yen)

	April 1, 2008 - December 31, 2008
Net sales	598,695
Cost of sales	118,810
Gross profit on sales	479,884
Provision for sales returns-net	45
Gross profit	479,839
Selling, general and administrative expenses*	406,423
Operating income	73,416
Non-operating income	
Interest income	2,725
Dividend income	953
Amortization of negative goodwill	243
Other	238
Total non-operating income	4,160
Non-operating expenses	
Interest expenses	5,554
Bond issue costs	348
Foreign exchange loss	4,344
Equity in loss of an associated company	74
Other	863
Total non-operating expenses	11,185
Ordinary income	66,391
Special gain	
Gain on sales of fixed assets	14
Gain on sales of investment securities	432
Gain on sale of a consolidated subsidiary	1,575
Other	28
Total special gain	2,050
Special loss	
Loss on disposal of fixed assets	220
Loss on impairment	905
Loss on devaluation of investment securities	6,093
Other	434
Total special loss	7,653
Income before income taxes and minority interests	60,787
Income taxes-current	38,703
Income taxes-deferred	(17,584)
Total Income taxes	21,119
Minority interests in net income	497
Net income	39,171

CONSOLIDATED STATEMENT OF INCOME (Three Months)

(millions of yen)

	October 1, 2008 - December 31, 2008
Net sales	199,866
Cost of sales	39,590
Gross profit on sales	160,275
Provision for sales returns-net	44
Gross profit	160,230
Selling, general and administrative expenses*	133,358
Operating income	26,871
Non-operating income	
Interest income	922
Dividend income	387
Amortization of negative goodwill	81
Other	47
Total non-operating income	1,438
Non-operating expenses	
Interest expenses	2,108
Foreign exchange loss	3,283
Equity in loss of an associated company	20
Other	116
Total non-operating expenses	5,528
Ordinary income	22,781
Special gain	
Gain on sales of fixed assets	4
Other	26
Total special gain	31
Special loss	
Loss on disposal of fixed assets	77
Loss on impairment	905
Loss on devaluation of investment securities	4,645
Other	3
Total special loss	5,631
Income before income taxes and minority interests	17,180
Income taxes-current	14,150
Income taxes-deferred	(7,604)
Total Income taxes	6,546
Minority interests in net income	175
Net income	10,458

3) CONSOLIDATED STATEMENT OF CASH FLOWS

(millions of yen)

	April 1, 2008 - December 31, 2008
Operating activities:	
Income before income taxes and minority interests	60,787
Depreciation and amortization	36,785
Amortization of goodwill	7,302
Other loss (income)	8,792
Decrease (Increase) in notes and accounts receivable-trade	(27,608)
Decrease (Increase) in inventories	(4,470)
Increase (Decrease) in notes and accounts payable-trade	3,835
Increase (Decrease) in other current liabilities	14,598
Increase (Decrease) in reserve for sales rebates	7,351
Other-net	475
Sub-total	107,849
Interest and dividends received	3,515
Interest paid	(4,518)
Income taxes-paid	(35,880)
Net cash provided by operating activities	70,965
Investing activities:	
Purchases of property, plant and equipment	(27,428)
Purchases of intangible assets	(4,039)
Purchases of securities	(1,390)
Proceeds from sales and redemption of securities	6,572
Other-net	(10,554)
Net cash used in investing activities	(36,839)
Financing activities:	
Net increase (decrease) in short-term borrowings	(317,539)
Proceeds from long-term borrowings	231,530
Proceeds from bonds and debentures	119,616
Dividends paid	(38,462)
Other-net	(1,218)
Net cash used in financing activities	(6,073)
Foreign currency translation adjustments on cash and cash equivalents	(17,694)
Net increase (decrease) in cash and cash equivalents	10,357
Cash and cash equivalents at beginning of period	119,950
Cash and cash equivalents at end of period	130,307

4) Going Concern

Not applicable

5) Segment Information

(1) Business Segment Information

Three months ended December 31, 2008

(millions of yen)

	Pharma-ceuticals	Other	Total	Eliminations and Corporate	Consolidated
Sales					
(1) Sales to external customers	194,336	5,529	199,866	-	199,866
(2) Intersegment sales	87	4,224	4,311	[4,311]	-
Total sales	194,424	9,754	204,178	[4,311]	199,866
Operating income	27,728	529	28,257	[1,385]	26,871

Nine months ended December 31, 2008

(millions of yen)

	Pharma-ceuticals	Other	Total	Eliminations and Corporate	Consolidated
Sales					
(1) Sales to external customers	582,786	15,908	598,695	-	598,695
(2) Intersegment sales	217	13,605	13,823	[13,823]	-
Total sales	583,004	29,514	612,518	[13,823]	598,695
Operating income	75,648	1,376	77,024	[3,608]	73,416

Note 1: The Company classifies consolidated operations into two segments: 'Pharmaceuticals', which includes prescription pharmaceuticals, and 'Other', which encompasses all operations other than pharmaceuticals.

Note 2: Major products in each segment are as follows:

Business segment	Major products
Pharmaceuticals	Prescription pharmaceuticals, Consumer health care products, Diagnostic pharmaceuticals, etc.
Other	Food additives, Chemicals, Machinery, Others

Note 3: Changes in accounting principles:

(Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statement)

As stated in "Changes in Accounting Policies and Presentation Methods in Quarterly Consolidated Financial Reports", effective from this fiscal year, the Company applied new Practical Issues Task Force (PITF) "Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statement (ASBJ PITF No.18, May 17, 2006) and accordingly made any necessary modifications to its consolidated financial statements. As a result, operating income for the current nine-month period decreased by ¥7,216 million in the Pharmaceuticals segment.

(Changes in amortization of property, plant and equipment)

As stated in "Changes in Accounting Policies and Presentation Methods in Quarterly Consolidated Financial Reports", Eisai and its domestic subsidiaries had amortized property, plant and equipment by the declining balance method, but from this fiscal year, the Company uses the straight line method, which has been used by Eisai's foreign subsidiaries. As a result, operating income for the current nine-month period increased by ¥1,178 million in the Pharmaceuticals segment and by ¥92 million in the Other segment, respectively.

In addition, the effect of adoption of a new treatment method on residual values in which depreciable assets are depreciated to 1 yen (the defined residual value) at the end of their useful life, was to decrease operating income by ¥976 million in the Pharmaceuticals segment, and ¥30 million in the Other segment, respectively.

The aggregate effect of the change to the straight line method and the change in residual value as stated above was to increase operating income by ¥201 million in the Pharmaceuticals segment and by ¥62 million in the Other segment, respectively.

(2) Geographical Segment Information

Three months ended December 31, 2008

(millions of yen)

	Japan	North America	Europe	China	Asia and others	Total	Eliminations and Corporate	Consolidated
Sales								
(1) Sales to external customers	92,191	89,813	11,576	2,562	3,721	199,866	-	199,866
(2) Intersegment sales	24,264	14,060	6,847	10	100	45,282	[45,282]	-
Total sales	116,456	103,873	18,423	2,573	3,822	245,149	[45,282]	199,866
Operating income	21,815	3,211	514	392	707	26,642	229	26,871

Nine months ended December 31, 2008

(millions of yen)

	Japan	North America	Europe	China	Asia and others	Total	Eliminations and Corporate	Consolidated
Sales								
(1) Sales to external customers	258,478	277,195	40,647	8,591	13,782	598,695	-	598,695
(2) Intersegment sales	75,790	44,187	24,034	25	319	144,357	[144,357]	-
Total sales	334,269	321,382	64,681	8,617	14,101	743,052	[144,357]	598,695
Operating income	60,925	6,878	2,675	1,729	3,126	75,336	[1,920]	73,416

Note 1: Segmentation by country or region is based on geographical proximity.

Note 2: Major areas and countries included in each region:

-North America: The United States and Canada

-Europe: The United Kingdom, France, Germany, etc.

-Asia and Others: East and South-East Asia, Latin America, etc., excluding China

Note 3: Intersegment sales in Japan principally represent product sales from Eisai Co., Ltd. (the 'Parent Company') to the overseas subsidiaries. Intersegment sales in North America, Europe, and Asia and Others are principally sales to the Parent Company from the overseas subsidiaries engaging in research and development.

Note 4: Changes in segmentation by country or region

Previously, the Company divided its geographical segment into four regions: "Japan", "North America", "Europe", and "Asia and others". Given that China has been expanding its presence, however, the Company appointed a vice president in charge of operations in China, and changed its promotional segment management structure. With this structural change, China is separated from "Asia and others" and separately posted from this fiscal year. As a result of this reclassification, net sales and operating income for "Asia and others" declined by an amount equal to the net sales and operating income for China.

Note 5: Changes in accounting principles:

(Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statement)

As stated in "Changes in Accounting Policies and Presentation Methods in Quarterly Consolidated Financial Reports", effective from this fiscal year, the Company applied new Practical Issues Task Force (PITF) "Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statement (ASBJ PITF No.18, May 17, 2006) and accordingly made any necessary modifications to its consolidated financial statements. Consequently, operating income in North America during the current nine-month period decreased by ¥7,183 million, and the impact of this change on Europe, China and Asia and other is insignificant.

(Changes in amortization of property, plant and equipment)

As stated in "Changes in Accounting Policies and Presentation Methods in Quarterly Consolidated Financial Reports", Eisai and its domestic subsidiaries had amortized property, plant and equipment by the declining balance method, but from this fiscal year, the Company uses the straight line method, which has been used by Eisai's foreign subsidiaries. As a result, operating income for the current nine-month period increased by ¥1,270 million in Japan.

In addition, depreciable assets are depreciated to 1 yen (the defined residual value) at the end of their useful life with the introduction of the new treatment method on residual value. As a result, operating income decreased by ¥1,006 million in Japan.

The aggregate effect of the change to the straight line method and the change in residual value as stated above was to increase operating income by ¥264 million in Japan.

(3) Overseas Sales

Three months ended December 31, 2008

(millions of yen)

	North America	Europe	China	Asia and Others	Total
Overseas sales	91,852	13,048	2,562	4,950	112,413
Consolidated sales					199,866
Share of overseas sales(%)	45.9	6.5	1.3	2.5	56.2

Nine months ended December 31, 2008

(millions of yen)

	North America	Europe	China	Asia and Others	Total
Overseas sales	284,235	50,006	8,591	16,866	359,699
Consolidated sales					598,695
Share of overseas sales(%)	47.5	8.4	1.4	2.8	60.1

Note 1: Segmentation of the areas is based on geographical proximity.
Note 2: Major areas and countries included in each region:
-North America: The United States and Canada.
-Europe: The United Kingdom, France, Germany, etc.
-Asia and Others: East and South-East Asia, Latin America, etc., excluding China
Note 3: Overseas sales represent the sales reported from the consolidated subsidiaries operating in countries and areas outside Japan.
Note 4: China is separated from “Asia and others” and separately posted from this fiscal year as stated in details in “Note 5” shown in the previous page. As a result of this reclassification, net sales and operating income for “Asia and others” declined by an amount equal to the net sales and operating income for China.

6) Changes in Equity

Not applicable

7) Notes to Consolidated Statement of Income

*Principal items included in “Selling, general and administrative expenses” are as follows:

Nine months ended December 31, 2008

Promotional expenses:	¥158,064 million
Research and development expenses:	¥116,927 million
Salaries and bonuses:	¥50,183 million

Three months ended December 31, 2008

Promotional expenses:	¥52,604 million
Research and development expenses:	¥38,878 million
Salaries and bonuses:	¥16,096 million

CONSOLIDATED STATEMENT OF INCOME (for reference)
Nine months ended December 31, 2007

	April 1, 2007 - December 31, 2007	
Account Title	(millions of yen)	
I. Net sales		559,553
II. Cost of sales		83,627
Gross profit on sales		475,926
Provision for (Reversal of) sales returns-net		(95)
Gross profit		476,021
III. Selling, general and administrative expenses		
1. Research and development expenses	99,568	
2. Selling, general and administrative expenses	283,912	383,481
Operating income		92,540
IV. Non-operating income		5,290
V. Non-operating expenses		1,556
Ordinary Income		96,275
VI. Special gain		2,266
VII. Special loss		1,479
Income before income taxes and minority interests		97,061
Income taxes-current	37,751	
Income taxes-deferred	(4,737)	33,013
Minority interests in net income		533
Net income		63,514

CONSOLIDATED STATEMENT OF INCOME (for reference)

Three months ended December 31, 2007

	October 1, 2007 - December 31, 2007	
Account Title	(millions of yen)	
I. Net sales		196,736
II. Cost of sales		28,933
Gross profit on sales		167,802
Provision for (Reversal of) sales returns-net		8
Gross profit		167,794
III. Selling, general and administrative expenses		
1. Research and development expenses	35,723	
2. Selling, general and administrative expenses	96,590	132,314
Operating income		35,479
IV. Non-operating income		1,942
V. Non-operating expenses		707
Ordinary income		36,714
VI. Special gain		8
VII. Special loss		380
Income before income taxes and minority interests		36,341
Income taxes-current	12,400	
Income taxes-deferred	(346)	12,054
Minority interests in net income		124
Net income		24,162

CONSOLIDATED STATEMENT OF CASH FLOWS (for reference)
Nine months ended December 31, 2007

Account Title	April 1, 2007 - December 31, 2007 (millions of yen)
I. Operating activities:	
1. Income before income taxes and minority interests	97,061
2. Depreciation and amortization	23,373
3. Loss on impairment	1
4. Increase (Decrease) in allowance for doubtful accounts	6
5. Interest and dividend income	(5,005)
6. Interest expenses	91
7. Equity in (earnings) loss	12
8. (Gain) Loss on sales and disposal of fixed assets	340
9. (Gain) Loss on sales of securities	(2,202)
10. Loss on devaluation of securities	242
11. (Increase) Decrease in notes and accounts receivables-trade	(18,026)
12. (Increase) Decrease in inventories	(3,067)
13. Increase (Decrease) in notes and accounts payable-trade	(2,300)
14. Increase (Decrease) in other current liabilities	9,275
15. Increase (Decrease) in reserve for sales rebates	1,812
16. Increase (Decrease) in liability for retirement benefits	(4,794)
17. Other-net	(1,545)
Sub-total	95,276
18. Interest and dividends received	4,774
19. Interest paid	(98)
20. Income taxes-paid	(48,100)
Net cash provided by operating activities	51,852
II. Investing activities:	
1. Purchases of short-term investment	(703)
2. Proceeds from sales and redemption of short-term investments	7,072
3. Purchases of property, plant and equipment	(24,577)
4. Proceeds from sales of property, plant and equipment	97
5. Purchases of intangible assets	(11,186)
6. Purchases of investment securities	(1,812)
7. Proceeds from sales and redemptions of investment securities	9,727
8. Payment for acquisition of business	(39,238)
9. Net (increase) decrease in time deposits (exceeding 3 months)	(163)
10. Other-net	(1,037)
Net cash used in investing activities	(61,821)
III. Financing activities:	
1. Net increase (decrease) in short-term borrowings	19,757
2. Dividends paid	(36,938)
3. Dividends paid to minority shareholders	(60)
4. Other-net	(222)
Net cash used in financing activities	(17,464)
IV. Foreign currency translation adjustments on cash and cash equivalents	(1,926)
V. Net increase (decrease) in cash and cash equivalents	(29,359)
VI. Cash and cash equivalents at beginning of period	171,090
VII. Cash and cash equivalents at end of period	141,731

Segment Information (for reference)

(1) Business Segment Information

Three months ended December 31, 2007

(millions of yen)

	Pharma-ceuticals	Other	Total	Eliminations and Corporate	Consolidated
Sales					
(1) Sales to external customers	190,959	5,776	196,736	-	196,736
(2) Intersegment sales	66	5,141	5,207	[5,207]	-
Total sales	191,025	10,918	201,943	[5,207]	196,736
Operating expenses	155,116	10,383	165,499	[4,242]	161,256
Operating income	35,909	534	36,443	[964]	35,479

Nine months ended December 31, 2007

(millions of yen)

	Pharma-ceuticals	Other	Total	Eliminations and Corporate	Consolidated
Sales					
(1) Sales to external customers	542,408	17,145	559,553	-	559,553
(2) Intersegment sales	161	14,356	14,517	[14,517]	-
Total sales	542,569	31,502	574,071	[14,517]	559,553
Operating expenses	448,453	29,978	478,431	[11,418]	467,013
Operating income	94,116	1,523	95,639	[3,099]	92,540

Note 1: The Company classifies consolidated operations into two segments: 'Pharmaceuticals', which includes prescription pharmaceuticals, and 'Other', which encompasses all operations other than pharmaceuticals.

Note 2: Major products in each segment are as follows:

Business segment	Major products
Pharmaceuticals	Prescription pharmaceuticals, Consumer health care products, Diagnostic pharmaceuticals, etc.
Other	Food additives, Chemicals, Machinery, Others

(2) Geographic Segment Information

Three months ended December 31, 2007

(millions of yen)

	Japan	North America	Europe	Asia and others	Total	Eliminations and Corporate	Consolidated
Net sales							
(1) Sales to external customers	89,138	86,046	14,346	7,204	196,736	-	196,736
(2) Intersegment sales	26,132	13,266	7,472	39	46,910	[46,910]	-
Total sales	115,270	99,313	21,819	7,243	243,646	[46,910]	196,736
Operating expenses	89,123	92,059	21,229	6,054	208,467	[47,210]	161,256
Operating income	26,146	7,253	590	1,189	35,179	299	35,479

Nine months ended December 31, 2007

(millions of yen)

	Japan	North America	Europe	Asia and others	Total	Eliminations and Corporate	Consolidated
Net sales							
(1) Sales to external customers	246,540	250,229	41,626	21,157	559,553	-	559,553
(2) Intersegment sales	77,950	37,257	19,833	75	135,117	[135,117]	-
Total sales	324,491	287,486	61,459	21,233	694,670	[135,117]	559,553
Operating expenses	252,500	270,513	59,981	16,929	599,924	[132,911]	467,013
Operating income	71,990	16,973	1,478	4,304	94,746	[2,205]	92,540

Note 1: Segmentation by country or region is based on geographic proximity.
Note 2: Major areas and countries included in each region:
-North America: The United States and Canada
-Europe: The United Kingdom, France, Germany, etc.
-Asia and Others: East and South-East Asia, Latin America, etc.
Note 3: Intersegment sales in Japan principally represent product sales from Eisai Co., Ltd. (the 'Parent Company') to the overseas subsidiaries. Intersegment sales in North America, Europe, and Asia and Others are principally sales to the Parent Company from the overseas subsidiaries engaging in research and development.

(3) Overseas Sales

Three months ended December 31, 2007

(millions of yen)

	North America	Europe	Asia and Others	Total
Overseas sales	89,484	18,255	7,974	115,714
Consolidated sales				196,736
Share of overseas sales (%)	45.5	9.3	4.0	58.8

Nine months ended December 31, 2007

(millions of yen)

	North America	Europe	Asia and Others	Total
Overseas sales	258,958	55,207	23,750	337,916
Consolidated sales				559,553
Share of overseas sales (%)	46.3	9.9	4.2	60.4

Note 1: Segmentation of the areas is based on geographic proximity.
Note 2: Major areas and countries included in each region:
-North America: The United States and Canada.
-Europe: The United Kingdom, France, Germany, etc.
-Asia and Others: East and South-East Asia, Latin America, etc
Note 3: Overseas sales represent the sales reported from the consolidated subsidiaries operating in countries and areas outside Japan.

Securities Code: 4523

2008.12

Reference Data

Third Quarter Ended December 31, 2008

January 30, 2009

Eisai Co., Ltd.

For Inquiries:

Public Relations / Investor Relations

TEL 81-3-3817-5120 FAX 81-3-3811-3077

http://www.eisai.co.jp/eir/

[Forward-looking Statements and Risk Factors]

Materials and information provided in this financial disclosure may contain “forward-looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions, such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to strategic alliances with partners, risks related to the acquisition of MGI PHARMA, INC., healthcare cost-containment measures, intensified competition with generic drugs, intellectual properties, possible incidence of adverse events, compliance with laws and regulations, litigations, closure or shutdown of factories, safety issues of raw materials used, outsourcing-related risks, environmental issues, IT security/information management, and conditions of financial markets, foreign exchange fluctuations, and internal control system.

Contents

* Revisions have been made to the full-year consolidated forecast announced in October 2008. The revised parts are underlined.
* All amounts are rounded to their nearest specified unit.
* The exchange rates utilized in the reference data are noted in the table below.
* All amounts of overseas profit and loss are converted into yen based on the average exchange rates for the periods shown in the table below.

Currency Exchange Rates

	US	EU	UK
	(¥/US$)	(¥/EURO)	(¥/£)
(Apr. 2007 - Dec. 2007) Nine Months Average Rate	117.28	162.82	236.51
(Dec. 31, 2007) Third Quarter End Rate	114.15	166.66	227.90
(Apr. 2007 - Mar. 2008) Fiscal Year Average Rate	114.28	161.52	229.44
(Mar. 31, 2008) Fiscal Year End Rate	100.19	158.19	200.11
(Apr. 2008 - Dec. 2008) Nine Months Average Rate	**102.84**	**150.70**	**187.25**
(Dec. 31, 2008) Third Quarter End Rate	**91.03**	**127.96**	**131.83**
(Jan. 2009 - Mar. 2009) Fourth Quarter Forecast Rate	**90.00**	**120.00**	**125.00**

<About indications in this Reference Data>

Eisai believes in cash generating ability as the most intrinsic element that decides the true value of a company. Upon this basic concept, we indicate that “cash income” and “cash EPS” are not affected by non-cash profit-and-loss items, such as depreciation of property, plant and equipment, amortization of goodwill, loss on impairment (including loss on devaluation of investment securities), and in-process R&D expenses.

Cash income

We consider that cash income is the total amount of cash available for investments for growth, business development, dividend payment, and repayment of borrowings, etc. We also consider that this is an indicator for cash generating ability (a managerial index for evaluating corporate growth potential and strategic appropriateness). Please note that we have partially changed the definition of cash income since this quarter as follows:

Cash income =Net income (loss) + Depreciation of PP&E and amortization of intangible assets + In-process R&D expenses + Amortization of goodwill + Loss on impairment (including loss on devaluation of investment securities)

Cash income per share (Cash EPS)

Cash EPS = Cash income / number of shares issued and outstanding (after deducting treasury stock)

In-process R&D expenses

The amounts assigned to product candidate compounds under development that have no alternative future use shall be charged to R&D expense at the acquisition date.

In accordance with the amendment of GAAP in Japan, indices or amounts presented for comparison with the same period in the previous fiscal year are indicated as "reference".

1. Consolidated Financial Highlights

1) Statements of Operation Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY %	2008	2009 est.
Net sales	559.6	**598.7**	107.0	734.3	780.0
Cost of sales	83.5	**118.9**	142.3	118.8	155.0
R&D expenses	99.6	**116.9**	117.4	225.4	152.0
SG&A expenses	283.9	**289.5**	102.0	372.3	378.5
Operating income	92.5	**73.4**	79.3	17.7	94.5
Ordinary income	96.3	**66.4**	69.0	18.9	82.5
Net income (loss)	63.5	**39.2**	61.7	(17.0)	46.0
Cash income	87.7	**90.0**	102.7	106.9	114.0
			YOY Inc./(Dec.)		
Dividend per share (DPS, yen)	-	-	-	130.0	140.0
Earnings (Loss) per Share (EPS, yen)	223.4	**137.5**	(85.9)	(59.8)	161.5
Cash income per share (Cash EPS, yen)	308.3	**315.9**	7.6	375.8	400.1

* "Cost of sales" includes "(Reversal of) Provision for sales returns-net".
* In accordance with the partial change of definition of "Cash income" as well as "Cash income per share", we have also changed the previous year's results based on the new definition.

<Additional Data>

Statements of Operation Data (Adjusted)

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				Full		
Apr - Dec	(GAAP) 2009	Accounting treatment of business combination	(Adjusted) **2009**	YOY %	(GAAP) 2009 est.	Accounting treatment of business combination	(Adjusted) 2009 est.
Net sales	598.7		**598.7**	107.0	780.0		780.0
Cost of sales	118.9	**14.4**	**104.4**	125.0	155.0	18.2	136.8
R&D expenses	116.9	**0.6**	**116.3**	116.8	152.0	0.8	151.2
SG&A expenses	289.5	**7.0**	**282.5**	99.5	378.5	9.0	369.5
Operating income	73.4	**[22.1]**	**95.5**	103.2	94.5	[28.0]	122.5
Ordinary income	66.4	**[22.1]**	**88.5**	91.9	82.5	[28.0]	110.5
Net income (loss)	39.2	**[16.7]**	**55.9**	88.0	46.0	[21.0]	67.0
				YOY Inc./(Dec.)			
Earnings per Share (EPS, yen)	137.5		**196.2**	(27.1)	161.5		235.2

* "Cost of sales" includes "(Reversal of) Provision for sales returns-net".

Adjusted: Financial reporting excluding non-cash accounting items from the business combination of MGI PHARMA, INC. in the previous period to clarify the actual performance of core business operations.

［Accounting treatment of business combinations］

Cost of sales: Amortization of sales rights, Increase of inventory
R&D expenses: Amortization of core technology
SG&A expenses: Amortization of goodwill

2) Statements of Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full
Apr - Dec	2008	**2009**	Inc./ (Dec.)	2008
Net cash provided by operating activities	51.9	**71.0**	19.1	73.2
Net cash used in investing activities	(61.8)	**(36.8)**	25.0	(476.4)
Net cash provided by (used in) financing activities	(17.5)	**(6.1)**	11.4	375.4
Cash and cash equivalents at end of period	141.7	**130.3**	(11.4)	120.0
Free cash flows	(23.1)	**39.5**	62.6	(415.9)

* "Free cash flows" = "Net cash provided by operating activities" - "Capital expenditures (including acquisition and other)"

3) Balance Sheets Data

(billions of yen)

	2008		Inc./
	Mar 31	**Dec 31**	(Dec.)
Total assets	1,123.9	**1,097.1**	(26.9)
Total liabilities	670.1	**697.2**	27.0
Bonds and debentures	1.0	**120.6**	119.6
Short-term & long-term borrowings	412.8	**318.7**	(94.1)
Total equity	453.8	**399.9**	(53.9)
Shareholders' Equity	448.9	**395.0**	(53.8)
Shareholders' Equity/Total assets (%)	39.9	**36.0**	(3.9)

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	Inc./ (Dec.)	2008	2009 est.
Capital expenditures	92.6	**27.9**	(64.8)	434.0	41.0
Property, plant and equipment	22.6	**24.0**	1.4	39.8	33.0
Intangible assets	70.1	**3.9**	(66.2)	394.3	8.0
Depreciation/Amortization	23.4	**36.8**	13.4	34.6	48.5

* Capital expenditures include the increase of asset by acquisition of Morphotek, Inc. and MGI PHARMA, INC..
* "Depreciation/Amortization" value includes amortization of "Intangible assets".

2. Consolidated Statements of Operation

(billions of yen)

Years Ended/Ending March 31 Apr - Dec	Nine months ended Dec 31						<Explanation>
	2008	Sales %	**2009**	Sales %	YOY %	Inc./ (Dec.)	
Net sales	559.6	100.0	**598.7**	100.0	107.0	39.1	**Net sales** <Reason for Increase> Increase in sales of *ARICEPT*, Contribution of *ALOXI* and *DACOGEN* <Reason for Decrease> Fluctuations in currency exchange rates
Cost of sales	83.6	14.9	**118.8**	19.8	142.1	35.2	
(Reversal of) Provision for sales returns-net	(0.1)	(0.0)	**0.0**	0.0		0.1	
Gross profit	476.0	85.1	**479.8**	80.1	100.8	3.8	
R&D expenses	99.6	17.8	**116.9**	19.5	117.4	17.4	**R&D expenses** <Reason for Increase> Progress of clinical studies
SG&A expenses	283.9	50.7	**289.5**	48.4	102.0	5.6	
Operating income	92.5	16.5	**73.4**	12.3	79.3	(19.1)	
Non-operating income:							
Interest and dividend income	5.0		**3.7**			(1.3)	
Other	0.3		**0.5**			0.2	
Total non-operating income	5.3	1.0	**4.2**	0.7		(1.1)	
Non-operating expenses:							**Interest expenses** <Reason for Increase> Increase in financing
Interest expenses	0.1		**5.6**			5.5	
Foreign exchange loss	1.0		**4.3**			3.4	
Other	0.5		**1.3**			0.8	
Total non-operating expense	1.6	0.3	**11.2**	1.9		9.6	
Ordinary income	96.3	17.2	**66.4**	11.1	69.0	(29.9)	
Special gain:							
Gain on sales of treasury stock	2.2		**2.0**			(0.2)	
Other	0.1		**0.0**			(0.0)	
Total special gain	2.3	0.4	**2.1**	0.3		(0.2)	
Special loss:							
Loss on devaluation of investment securities	0.2		**6.1**			5.9	**Loss on devaluation of investment securities** <Reason for Increase> Decline in market price of shares held
Other	1.2		**1.6**			0.3	
Total special loss	1.5	0.3	**7.7**	1.3		6.2	
Income before income taxes and minority interests	97.1	17.3	**60.8**	10.2	62.6	(36.3)	
Income taxes-current	37.8	6.7	**38.7**	6.5	102.5	1.0	
Income taxes-deferred	(4.7)	(0.8)	**(17.6)**	(2.9)		(12.8)	
Minority interests in net income	0.5	0.0	**0.5**	0.1		(0.0)	
Net income (loss)	63.5	11.4	**39.2**	6.5	61.7	(24.3)	
<Cash generating ability>							
Net income (loss)	63.5	11.4	**39.2**	6.5	61.7	(24.3)	
Depreciation of PP&E and amortization of intangible assets	21.1		**20.9**			(0.2)	
Amortization of intangible assets obtained by acquisition	2.2		**15.9**			13.7	
In-process R&D expenses	0.6		**-**			(0.6)	
Amortization of goodwill	0.0		**7.1**			7.0	
Impairment loss on long-lived assets	0.2		**7.0**			6.8	
Cash income	87.7	15.7	**90.0**	15.0	102.7	2.3	

* We have changed the previous year's results in accordance with a partial change of definition.

3. Consolidated Statements of Cash Flows

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			<Explanation>
Apr - Dec	2008	**2009**	Inc./ (Dec.)	
Operating activities:				
Income before income taxes and minority interests in net income	97.1	**60.8**	(36.3)	
Depreciation and amortization	23.4	**36.8**	13.4	
Net increase (decrease) in notes and accounts receivables/payable-trade and inventories	(23.4)	**(28.2)**	(4.8)	
Net increase (decrease) in accounts payable-other/accrued expenses etc.	9.3	**14.6**	5.3	
Other-net	(11.0)	**23.9**	35.0	**Other-net** <Reason for Increase> Booking of amortization of goodwill Booking of loss on devaluation of investment securities
[Sub-total]	95.3	**107.8**	12.6	
Interest paid/received	4.7	**(1.0)**	(5.7)	
Income taxes paid	(48.1)	**(35.9)**	12.2	
Net cash provided by operating activities	51.9	**71.0**	19.1	
Investing activities:				
Capital expenditures (including acquisition and other)	(74.9)	**(31.4)**	43.5	**Capital expenditures (including acquisition and other)** <Reason for Decrease> Impact from company acquisitions occurred in previous year
Purchases/proceeds from sales of securities etc.	14.3	**5.2**	(9.1)	
Other-net	(1.2)	**(10.6)**	(9.4)	
Net cash used in investing activities	(61.8)	**(36.8)**	25.0	
Financing activities:				
Net increase (decrease) in short-term borrowings	19.8	**(317.5)**	(337.3)	**Net increase (decrease) in short-term borrowings**
Proceeds from long-term borrowings	-	**231.5**	231.5	**Proceeds from long-term borrowings**
Proceeds from bonds and debentures	-	**119.6**	119.6	**Proceeds from bonds and debentures**
Dividends paid	(36.9)	**(38.5)**	(1.5)	
Other-net	(0.3)	**(1.2)**	(0.9)	
Net cash provided by (used in) financing activities	(17.5)	**(6.1)**	11.4	<Reason for Increase/Decrease> Financing for acquisition (Shift borrowings from short-term to long-term)
Foreign currency translation adjustments on cash and cash equivalents	(1.9)	**(17.7)**	(15.8)	
Net increase (decrease) in cash and cash equivalents	(29.4)	**10.4**	39.7	
Cash and cash equivalents at beginning of period	171.1	**120.0**	(51.1)	
Cash and cash equivalents at end of period	141.7	**130.3**	(11.4)	
Free Cash Flows	(23.1)	**39.5**	62.6	

* "Free cash flows" = "Net cash provided by operating activities" - "Capital expenditures (including acquisition and other)"

4. Financial Results by Business Segment

1) Consolidated Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Net sales to customers	559.6	**598.7**	734.3
Pharmaceuticals	542.4	**582.8**	711.8
Japan	231.1	**245.0**	292.7
North America	249.4	**275.8**	338.2
Europe	40.8	**39.7**	53.2
China	7.1	**8.6**	9.5
Asia and others	14.1	**13.8**	18.3
Other segment	17.1	**15.9**	22.4
Japan	15.5	**13.5**	20.0
Overseas	1.7	**2.4**	2.4

* Net sales to external customers for each segment.

* Major areas and countries included in each region:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, France, Germany, etc.
3. Asia and others: Asian countries except Japan and China, and South America, etc.

2) Consolidated Operating Income by Business Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Operating income	92.5	**73.4**	17.7
Pharmaceuticals	94.1	**75.6**	19.8
Other	1.5	**1.4**	1.9
Eliminations and corporate	(3.1)	**(3.6)**	(4.0)

* We deducted the figures specific for the accounting treatment of business combinations (non-cash items) with the acquisition of MGI PHARMA, INC. from the current GAAP basis figures. The operating income of Pharmaceuticals for nine months ended Dec.31, 2008 on an adjusted basis is ¥97.7 billion.

3) Geographical Segment Information

(1) Consolidated Net Sales by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Net sales to customers	559.6	**598.7**	734.3
Japan	246.5	**258.5**	312.7
North America	250.2	**277.2**	339.4
Europe	41.6	**40.6**	54.4
China	7.1	**8.6**	9.5
Asia and others	14.1	**13.8**	18.3
Overseas sales	313.0	**340.2**	421.6
Overseas sales (%)	55.9	**56.8**	57.4

* Net sales to external customers for each segment.

(2) Consolidated Operating Income by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Operating income	92.5	**73.4**	17.7
Japan	72.0	**60.9**	80.5
North America	17.0	**6.9**	(66.9)
Europe	1.5	**2.7**	1.8
China	1.4	**1.7**	2.0
Asia and others	2.9	**3.1**	3.7
Eliminations and corporate	(2.2)	**(1.9)**	(3.3)

* We deducted the figures specific for the accounting treatment of business combinations (non-cash items) with the acquisition of MGI PHARMA, INC. from the current GAAP basis figures. The operating income of North America for nine months ended Dec.31, 2008 on an adjusted basis is ¥29.0 billion.

4) Overseas Sales

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Net sales	559.6	**598.7**	734.3
Overseas sales	337.9	**359.7**	454.6
North America	259.0	**284.2**	350.4
Europe	55.2	**50.0**	73.1
China	7.1	**8.6**	9.5
Asia and others	16.7	**16.9**	21.5
Overseas sales (%)	60.4	**60.1**	61.9

* Major areas and countries included in each category in this page:
1. North America: The U.S. and Canada
2. Europe: The United Kingdom, France, Germany, etc.
3. Asia and Others: Asian countries except Japan and China, and South America, etc.

5) Global Product Sales by Geographical Area (Eisai Territory Sales)

(1) ***ARICEPT*** (Alzheimer's disease treatment)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
Japan	¥ Billions	49.0	**61.0**	62.3
U.S.	¥ Billions	137.5	**139.1**	186.9
	[U.S. $ Millions]	[1,173]	**[1,353]**	[1,635]
Europe Total	¥ Billions	26.3	**23.0**	33.3
UK	¥ Billions	1.0	**2.5**	1.4
	[UK £ Millions]	[4]	**[14]**	[6]
France	¥ Billions	19.5	**13.9**	24.3
	[Euro Millions]	[120]	**[92]**	[151]
Germany	¥ Billions	5.8	**6.5**	7.6
	[Euro Millions]	[36]	**[43]**	[47]
China	¥ Billions	0.7	**0.7**	1.2
	[Chinese RMB Millions]	[42]	**[46]**	[75]
Asia (excluding Japan and China)	¥ Billions	5.6	**5.2**	7.4
Total	¥ Billions	219.1	**229.0**	291.0

* Sales forecast for Eisai sales territories for the year ending on March 31, 2009 is ¥ 303.0 billion.

(2) ***ACIPHEX/PARIET*** (Proton pump inhibitor)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
Japan	¥ Billions	29.5	**35.0**	37.1
U.S.	¥ Billions	99.5	**76.5**	124.7
	[U.S. $ Millions]	[848]	**[744]**	[1,091]
Europe Total	¥ Billions	6.6	**7.5**	8.6
UK	¥ Billions	1.8	**1.8**	2.2
	[UK £ Millions]	[8]	**[10]**	[9]
Germany	¥ Billions	1.3	**1.8**	1.8
	[Euro Millions]	[8]	**[12]**	[11]
Italy	¥ Billions	3.4	**3.3**	4.5
	[Euro Millions]	[21]	**[22]**	[28]
China	¥ Billions	0.5	**0.5**	0.7
	[Chinese RMB Millions]	[33]	**[35]**	[43]
Asia (excluding Japan and China)	¥ Billions	3.9	**3.6**	4.8
Total	¥ Billions	139.9	**123.2**	175.9

* Sales forecast for Eisai sales territories for the year ending on March 31, 2009 is ¥ 157.0 billion.

* Average exchange rate of Japanese yen to Chinese RMB

April 1, 2007 to December 31, 2007	15.51 yen/Chinese RMB
April 1, 2008 to December 31, 2008	14.95 yen/Chinese RMB
April 1, 2007 to March 31, 2008	15.30 yen/Chinese RMB

(3) ***METHYCOBAL*** (Peripheral neuropathy treatment)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
Japan	¥ Billions	25.3	**24.7**	31.7
Asia (Including China)	¥ Billions	5.4	**6.6**	7.1
Total	¥ Billions	30.7	**31.3**	38.7

(4) ***ALOXI*** (Antiemetic agent)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
U.S.	¥ Billions	-	**28.0**	6.5
	[U.S. $ Millions]	[-]	**[272]**	[62]

(5) ***DACOGEN*** (Anticancer properties through inhibition of DNA methylation)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
U.S.	¥ Billions	-	**12.6**	2.7
	[U.S. $ Millions]	[-]	**[122]**	[26]

(6) ***ZONEGRAN*** (Anti-epileptic drug)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Area				
U.S.	¥ Billions	1.8	**1.6**	2.2
	[U.S. $ Millions]	[16]	**[16]**	[19]
Europe	¥ Billions	2.5	**2.9**	3.2
Asia	¥ Billions	0.1	**0.2**	0.2
Total	¥ Billions	4.4	**4.7**	5.6

6) SG&A Expenses

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		Full
Apr - Dec	2008	**2009**	2008
Net sales	559.6	**598.7**	734.3
SG&A expenses	283.9	**289.5**	372.3
Personnel expenses	56.0	**62.4**	77.1
Marketing promotion expenses	187.2	**181.0**	241.9
Administrative expenses and others	40.7	**46.1**	53.3
Ratio of SG&A expenses to net sales (%)	50.7	**48.4**	50.7

7) Eisai Inc. (U.S.)

Years Ended/Ending March 31		Nine months ended Dec 31		Full
Apr - Dec		2008	**2009**	2008
Net sales	¥ Billions	252.8	**263.4**	332.7
	[U.S. $ Millions]	[2,156]	**[2,561]**	[2,911]
Net sales of former MGI PHARMA	[U.S. $ Millions]	[-]	**[290]**	[-]
Operating income	¥ Billions	18.1	**19.5**	25.2
	[U.S. $ Millions]	[154]	**[189]**	[221]
Net income	¥ Billions	12.5	**13.4**	17.1
	[U.S. $ Millions]	[107]	**[130]**	[149]
Operating income before royalty deduction	¥ Billions	65.1	**63.8**	87.7
	[U.S. $ Millions]	[555]	**[620]**	[767]

*The sales function of MGI PHARMA has been integrated into Eisai Inc. since July 2008.

5. Consolidated Balance Sheets

1) Consolidated Balance Sheets <Assets>

(billions of yen)

	2008				Change	Inc./	<Explanation>
	Mar 31	%	**Dec 31**	%	%	(Dec.)	
Current assets:							
Cash and cash in banks	68.6		**58.0**			(10.6)	
Notes and accounts receivable-trade	172.1		**190.6**			18.4	
Short-term investments	56.3		**87.1**			30.8	
Inventories	58.1		**56.1**			(2.0)	
Deferred tax assets	35.4		**33.6**			(1.8)	
Other	25.4		**16.3**			(9.0)	
Allowance for doubtful receivables	(0.3)		**(0.3)**			0.0	
Total current assets	415.6	37.0	**441.3**	40.2	106.2	25.7	
Non-current assets:							
Property, plant and equipment:							
Buildings and structures	70.8		**68.1**			(2.6)	
Machinery, equipment and vehicles	23.1		**20.4**			(2.7)	
Land	20.8		**19.6**			(1.3)	
Construction in progress	19.8		**28.2**			8.4	
Other	12.6		**12.9**			0.3	
Total property, plant and equipment	147.1	13.1	**149.3**	13.6	101.5	2.2	
Intangible assets:							
Goodwill	178.7		**159.1**			(19.6)	
Sales rights	164.2		**135.8**			(28.5)	
Core technology	61.3		**53.5**			(7.8)	**Intangible assets** <Reason for Decrease> Fluctuations in currency exchange rates Amortization of intangible assets
Other	13.4		**12.1**			(1.3)	
Total Intangible assets	417.7	37.1	**360.5**	32.9	86.3	(57.2)	
Investments and other assets:							
Investment securities	89.5		**66.9**			(22.6)	**Investment securities** <Reason for Decrease> Decline in market price of shares held
Deferred tax assets	43.7		**65.5**			21.9	
Other	11.0		**14.0**			3.0	
Allowance for doubtful accounts	(0.6)		**(0.5)**			0.1	
Total investments and other assets	143.6	12.8	**146.0**	13.3	101.7	2.4	
Total non-current assets	708.4	63.0	**655.8**	59.8	92.6	(52.6)	
Total assets	1,123.9	100.0	**1,097.1**	100.0	97.6	(26.9)	

2) Consolidated Balance Sheets <Liabilities and Equity>

(billions of yen)

	2008				Change	Inc./	<Explanation>
	Mar 31	%	**Dec 31**	%	%	(Dec.)	
Current liabilities:							
Notes and accounts payable-trade	18.3		**18.1**			(0.2)	
Short-term borrowings	362.8		**45.0**			(317.8)	**Short-term borrowings** <Reason for Decrease> Shift to bonds and debenture and long-term borrowings
Accounts payable-other/accrued expenses etc.	116.7		**109.3**			(7.4)	
Income taxes payable	16.1		**15.4**			(0.7)	
Reserve for sales rebates	23.3		**27.7**			4.4	
Other	6.0		**11.8**			5.8	
Total current liabilities	543.2	48.3	**227.3**	20.7	41.9	(315.9)	
Long-term liabilities:							**Bonds and debentures** <Reason for Increase> Issuance of unsecured straight bonds
Bonds and debentures	0.8		**120.6**			119.8	
Long-term borrowings	50.0		**273.7**			223.7	**Long-term borrowings** <Reason for Increase> Financing for acquisition
Deferred tax liabilities	40.2		**32.3**			(8.0)	
Liability for retirement benefits	24.1		**22.5**			(1.7)	
Retirement allowances for directors	2.1		**2.3**			0.1	
Other	9.6		**18.6**			8.9	
Total long-term liabilities	127.0	11.3	**469.9**	42.8	370.1	342.9	
Total liabilities	670.1	59.6	**697.2**	63.6	104.0	27.0	
Owners' equity:							
Common stock	45.0		**45.0**			-	
Capital surplus	57.0		**57.0**			(0.0)	
Retained earnings	416.0		**414.8**			(1.2)	
Treasury stock	(39.7)		**(39.7)**			0.0	
Total owners' equity	478.2	42.5	**477.0**	43.5	99.8	(1.2)	
Net unrealized gain (loss) and translation adjustments:							
Net unrealized gain (loss) on available-for-sale securities	9.5		**3.4**			(6.1)	
Deferred gain (loss) on derivatives under hedge accounting	-		**(0.7)**			(0.7)	
Foreign currency translation adjustments	(38.9)		**(84.7)**			(45.8)	**Foreign currency translation adjustments** <Reason for Decrease> Changing B/S conversion rate in asset in overseas subsidiaries (US$:100.19 yen to 91.03 yen)
Total net unrealized gain (loss) and translation adjustments	(29.4)	(2.6)	**(82.0)**	(7.5)	-	(52.6)	
Stock acquisition rights	0.6	0.1	**0.6**	0.1	106.8	0.0	
Minority interests	4.4	0.4	**4.2**	0.4	96.5	(0.2)	
Total equity	453.8	40.4	**399.9**	36.4	88.1	(53.9)	
Total liabilities and equity	1,123.9	100.0	**1,097.1**	100.0	97.6	(26.9)	

6. Consolidated Changes in Quarterly Results

1) Statements of Operation Data

(billions of yen)

Years Ended/Ending March 31	2008				2009		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Net sales	176.0	186.8	196.7	174.7	195.8	203.0	**199.9**
Cost of sales	27.5	27.1	28.9	35.3	39.4	39.9	**39.6**
R&D expenses	30.5	33.3	35.7	125.9	35.7	42.3	**38.9**
SG&A expenses	91.8	95.5	96.6	88.4	96.7	98.4	**94.5**
Operating income (loss)	26.2	30.9	35.5	(74.8)	24.1	22.5	**26.9**
Non-operating gain & loss	2.2	0.3	1.2	(2.6)	(0.2)	(2.7)	**(4.1)**
Ordinary income (loss)	28.4	31.2	36.7	(77.4)	23.9	19.7	**22.8**
Special gain & loss	2.2	(1.0)	(0.4)	(2.0)	1.3	(1.3)	**(5.6)**
Income (loss) before income taxes and minority interests in income	30.6	30.2	36.3	(79.4)	25.2	18.4	**17.2**
Net income (loss)	19.3	20.0	24.2	(80.5)	16.6	12.1	**10.5**
Cash Income	27.3	28.1	32.3	19.2	31.8	27.9	**30.3**
Earnings (loss) per share, yen	68.1	70.4	84.9	(283.2)	58.4	42.4	**36.7**
Cash income per share (Cash EPS, yen)	96.0	98.8	113.5	67.5	111.8	97.9	**106.2**

* "Cost of Sales" includes "(Reversal of) Provision for sales returns-net".
* In accordance with the partial change of definition of "Cash income" as well as "Cash income per share", we have also changed the previous year's results based on the new definition.

2) Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	2008				2009		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Net cash provided by operating activities	7.8	33.9	10.1	21.4	18.6	50.8	**1.6**
Net cash used in investing activities	(46.0)	(6.7)	(9.2)	(414.6)	(7.7)	(9.3)	**(19.8)**
Net cash provided by (used in) financing activities	(18.7)	(0.1)	1.3	392.8	(20.0)	(5.5)	**19.5**
Cash and cash equivalents at end of period	119.6	141.0	141.7	120.0	113.0	142.1	**130.3**
Free cash flows	(46.1)	24.8	(1.7)	(392.8)	6.3	40.0	**(6.7)**

* "Free cash flows" = "Net cash provided by operating activities" - "Capital expenditures (including acquisition and other)"

3) Balance Sheets Data

<Assets>

(billions of yen)

	2007			2008			
	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30	**Dec 31**
Current assets	396.0	420.9	430.9	415.6	433.4	444.2	**441.3**
Property, plant and equipment	135.3	137.5	141.4	147.1	155.0	157.6	**149.3**
Intangible assets	104.0	121.6	120.4	417.7	430.3	410.8	**360.5**
Investments and other assets	150.4	137.7	140.6	143.6	146.6	144.0	**146.0**
Non-current assets	389.7	396.8	402.4	708.4	731.9	712.3	**655.8**
Total assets	785.7	817.6	833.3	1,123.9	1,165.3	1,156.5	**1,097.1**

<Liabilities and Equity>

(billions of yen)

	2007			2008			
	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30	**Dec 31**
Current liabilities	180.6	191.8	205.7	543.2	367.1	209.9	**227.3**
Long-term liabilities	36.7	50.8	51.1	127.0	324.4	481.8	**469.9**
Total liabilities	217.2	242.5	256.8	670.1	691.5	691.6	**697.2**
Owners' equity	528.0	548.9	558.7	478.2	474.5	486.6	**477.0**
Net unrealized gain (loss) and translation adjustments	30.0	15.4	12.8	(29.4)	(5.4)	(26.6)	**(82.0)**
Stock acquisition rights	0.3	0.6	0.6	0.6	0.6	0.6	**0.6**
Minority interests	10.2	10.3	4.5	4.4	4.3	4.3	**4.2**
Total equity	568.5	575.1	576.5	453.8	473.9	464.9	**399.9**
Total liabilities and equity	785.7	817.6	833.3	1,123.9	1,165.3	1,156.5	**1,097.1**

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	2008				2009		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Capital expenditures	46.2	35.3	11.1	341.4	8.5	12.3	**7.1**
Property, plant and equipment	3.9	9.7	8.9	17.2	7.5	10.3	**6.2**
Intangible assets	42.3	25.6	2.2	324.2	1.0	2.0	**0.9**
Depreciation/Amortization	7.3	8.1	8.0	11.2	12.3	12.6	**11.9**

* Capital expenditures include the increase of assets through the acquisition of Morphotek, Inc. and MGI PHARMA, INC.

* "Depreciation/Amortization" includes amortization of "Intangible assets".

5) *ARICEPT* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Japan	¥ Billions	14.9	15.1	18.9	13.3	19.4	18.8	**22.7**
U.S.	¥ Billions	41.5	48.0	48.0	49.4	43.4	49.9	**45.8**
	[U.S. $ Millions]	[343]	[407]	[423]	[463]	[415]	[464]	**[474]**
Europe	¥ Billions	9.2	8.1	9.0	6.9	8.0	8.7	**6.3**
UK	¥ Billions	0.3	0.3	0.4	0.3	0.7	1.3	**0.5**
	[UK £ Millions]	[1]	[1]	[2]	[2]	[4]	[6]	**[4]**
France	¥ Billions	7.0	5.9	6.6	4.8	5.1	5.0	**3.8**
	[Euro Millions]	[43]	[36]	[40]	[31]	[31]	[31]	**[30]**
Germany	¥ Billions	1.9	1.9	2.0	1.8	2.1	2.4	**2.0**
	[Euro Millions]	[12]	[12]	[12]	[11]	[13]	[15]	**[15]**
China	¥ Billions	0.0	0.3	0.3	0.5	0.1	0.3	**0.2**
	[Chinese RMB Millions]	[3]	[22]	[17]	[33]	[9]	[20]	**[18]**
Asia (excluding Japan and China)	¥ Billions	1.7	1.9	2.0	1.8	2.0	2.0	**1.2**
Total	¥ Billions	67.3	73.5	78.2	71.9	72.9	79.6	**76.4**

6) *ACIPHEX/PARIET* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Japan	¥ Billions	8.9	9.3	11.2	7.6	11.0	10.6	**13.4**
U.S.	¥ Billions	31.8	34.6	33.1	25.2	25.9	27.0	**23.6**
	[U.S. $ Millions]	[263]	[293]	[292]	[243]	[248]	[251]	**[245]**
Europe	¥ Billions	2.5	2.1	1.9	2.0	2.5	2.6	**2.5**
UK	¥ Billions	0.8	0.7	0.4	0.4	0.6	0.7	**0.4**
	[UK £ Millions]	[3]	[3]	[2]	[2]	[3]	[3]	**[3]**
Germany	¥ Billions	0.5	0.3	0.4	0.5	0.6	0.7	**0.5**
	[Euro Millions]	[3]	[2]	[2]	[3]	[4]	[4]	**[4]**
Italy	¥ Billions	1.2	1.1	1.1	1.2	1.2	1.2	**1.0**
	[Euro Millions]	[7]	[7]	[7]	[7]	[7]	[7]	**[8]**
China	¥ Billions	0.2	0.2	0.1	0.1	0.1	0.2	**0.2**
	[Chinese RMB Millions]	[14]	[10]	[9]	[10]	[9]	[13]	**[13]**
Asia (excluding Japan and China)	¥ Billions	1.4	1.2	1.3	1.0	1.3	1.3	**1.0**
Total	¥ Billions	44.9	47.3	47.7	36.0	40.8	41.7	**40.6**

7) *METHYCOBAL* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Japan	¥ Billions	8.2	8.0	9.1	6.4	8.3	7.7	**8.7**
Asia (including China)	¥ Billions	1.8	1.8	1.7	1.7	2.4	2.4	**1.8**
Total	¥ Billions	10.1	9.8	10.8	8.1	10.7	10.1	**10.5**

8) *ALOXI* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
U.S.	¥ Billions	-	-	-	6.5	9.5	9.5	**9.1**
	[U.S. $ Millions]	[-]	[-]	[-]	[62]	[90]	[88]	**[94]**

9) *DACOGEN* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
U.S.	¥ Billions	-	-	-	2.7	4.4	4.3	**3.9**
	[U.S. $ Millions]	[-]	[-]	[-]	[26]	[42]	[40]	**[41]**

10) *ZONEGRAN* Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
U.S.	¥ Billions	0.7	0.7	0.4	0.4	0.5	0.6	**0.6**
	[U.S. $ Millions]	[6]	[6]	[4]	[4]	[4]	[5]	**[6]**
Europe	¥ Billions	0.7	0.8	0.9	0.8	1.0	1.0	**0.9**
Asia	¥ Billions	0.0	0.0	0.0	0.1	0.1	0.1	**0.0**
Total	¥ Billions	1.5	1.6	1.4	1.2	1.5	1.6	**1.5**

11) Eisai Inc. (U.S.)

Years Ended/Ending March 31		2008				2009		
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	**Third Quarter**
Net sales	¥ Billions	77.8	88.3	86.7	79.9	74.8	98.0	**90.6**
	[U.S. $ Millions]	[644]	[748]	[764]	[756]	[716]	[913]	**[932]**
Net sales of former MGI PHARMA	[U.S. $ Millions]	[-]	[-]	[-]	[-]	[-]	[142]	**[148]**
Operating income	¥ Billions	3.6	7.1	7.4	7.1	4.0	8.1	**7.4**
	[U.S. $ Millions]	[29]	[60]	[65]	[66]	[39]	[75]	**[76]**
Net income	¥ Billions	2.6	4.9	5.0	4.6	2.6	5.2	**5.6**
	[U.S. $ Millions]	[22]	[41]	[44]	[43]	[25]	[48]	**[57]**
Operating income before royalty deduction	¥ Billions	18.0	23.5	23.6	22.6	18.1	23.9	**21.8**
	[U.S. $ Millions]	[149]	[199]	[207]	[212]	[174]	[222]	**[225]**

*The sales function of MGI PHARMA has been integrated into Eisai Inc. since July 2008.

7. Non-Consolidated Financial Highlights

1) Non-Consolidated Financial Highlights

(1) Statements of Income Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY **%**	2008	2009 est.
Net sales	302.8	**313.3**	103.5	389.2	401.0
Cost of sales	59.6	**63.3**	106.1	76.0	80.0
R&D expenses	96.5	**108.0**	111.9	134.0	140.0
SG&A expenses	80.4	**87.4**	108.7	106.1	113.5
Operating income	66.2	**54.6**	82.5	73.1	67.5
Ordinary income	66.6	**48.7**	73.2	71.0	57.5
Net income	44.3	**33.5**	75.7	46.0	36.0

* "Cost of sales" includes "(Reversal of) Provision for sales returns-net".

(2) Statements of Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full
Apr - Dec	2008	**2009**	Inc./ (Dec.)	2008
Net cash provided by operating activities	15.9	**18.5**	2.7	36.7
Net cash provided by (used in) investing activities	(20.8)	**50.0**	70.8	(431.3)
Net cash provided by (used in) financing activities	(17.0)	**(77.7)**	(60.7)	375.8
Cash and cash equivalents at end of period	24.6	**18.5**	(6.1)	27.7
Free cash flows	(3.3)	**6.4**	9.6	9.6

* "Free cash flows" = "Net cash provided by operating activities" - "Capital expenditures (including acquisition and other)"

(3) Balance Sheets Data

(billions of yen)

	2008		Inc./
	Mar 31	**Dec 31**	(Dec.)
Total assets	977.3	**926.2**	(51.0)
Total liabilities	505.9	**467.1**	(38.8)
Total equity	471.4	**459.1**	(12.2)
Shareholders' Equity	470.8	**458.5**	(11.6)
Shareholders' Equity/Total assets (%)	48.2	**49.6**	1.4

(4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	Inc./ (Dec.)	2008	2009 est.
Capital expenditures	15.4	**9.4**	(6.0)	24.9	15.0
Property, plant and equipment	7.3	**6.9**	(0.3)	15.2	10.0
Intangible assets	8.1	**2.5**	(5.6)	9.7	5.0
Depreciation/Amortization	13.0	**13.2**	0.1	17.8	17.5

* "Depreciation/Amortization" includes amortization of "Intangible assets".

2) Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY **%**	2008	2009 est.
Net sales	302.8	**313.3**	103.5	389.2	401.0
Prescription pharmaceuticals	184.9	**204.0**	110.3	231.8	258.5
Pharmaceuticals exports	44.6	**39.9**	89.6	60.7	51.0
Consumer health care products	15.4	**14.7**	95.3	20.1	19.0
Other (Food additives/Chemicals, etc.)	1.0	**1.2**	115.0	1.4	1.5
Industrial property rights, and other income	56.8	**53.5**	94.1	75.3	71.0

3) Exports by Geographical Area

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full
Apr - Dec	2008	**2009**	YOY **%**	2008
Net Sales	302.8	**313.3**	103.5	389.2
Exports	101.1	**93.0**	92.0	135.6
North America	73.2	**67.8**	92.5	98.0
Europe	22.6	**18.5**	81.8	29.7
Asia and Others (including China)	5.3	**6.8**	127.7	7.9
Ratio of exports to sales (%)	33.4	**29.7**	-	34.8

* Major areas and countries included in each region:
1. North America: The U.S. and Canada
2. Europe: The United Kingdom, France, Germany, etc.
3. Asia and others: East Asia, South-East Asia, and Central and South America, etc. excluding Japan

* The figures in "Exports" include revenues from industrial property rights, etc.

4) Prescription Pharmaceuticals

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY	2008	2009
Description / *Product*			**%**		est.
Alzheimer's disease treatment *ARICEPT*	49.0	**61.0**	124.5	62.3	78.0
Proton pump inhibitor *PARIET*	29.5	**35.0**	118.7	37.1	43.5
Peripheral neuropathy treatment *METHYCOBAL*	25.3	**24.7**	97.7	31.7	31.0
Gastritis/gastric ulcer treatment *SELBEX*	14.6	**12.7**	86.8	18.2	16.0
Osteoporosis treatment *ACTONEL*	6.9	**7.0**	102.0	8.2	9.0
Muscle relaxant *MYONAL*	6.4	**6.1**	94.8	8.0	7.5
Non-ionic contrast medium *IOMERON*	6.4	**5.7**	88.7	7.9	7.5
Osteoporosis treatment *GLAKAY*	5.3	**4.4**	82.4	6.4	5.5
Genetically engineered glucagon preparation *GLUCAGON G NOVO*	3.2	**3.0**	94.9	3.9	3.5
Long-acting isosorbide denigrate preparation *NITOROL-R*	2.7	**2.4**	87.8	3.4	3.0
Fully-human monoclonal anti-TNF-alpha antibody *HUMIRA*	-	**1.2**	-	-	2.0
Others	35.5	**40.8**	114.8	44.7	52.0
Prescription pharmaceuticals total	184.9	**204.0**	110.3	231.8	258.5

5) Exports by Products

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY	2008	2009
Product			**%**		est.
ARICEPT	20.8	**19.8**	95.2	28.1	24.5
ACIPHEX/PARIET	18.4	**13.5**	73.3	25.1	18.0
Others	5.3	**6.6**	123.9	7.5	8.5
Exports total	44.6	**39.9**	89.6	60.7	51.0

6) Consumer Health Care Products

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			Full	
Apr - Dec	2008	**2009**	YOY	2008	2009
Description / *Product*			**%**		est.
Vitamin B_2 preparation *CHOCOLA BB* Group	7.4	**7.8**	104.9	9.5	10.0
Active-type Vitamin B_{12} *NABOLIN* Group	1.7	**1.7**	97.3	2.3	2.0
JUVELUX / Natural Vitamin E preparation *Vitamin-E* Group	1.3	**1.2**	91.8	1.7	1.5
Stomach ache and heartburn treatment *SACLON* Group	1.2	**1.1**	89.8	1.6	1.5
Others	3.7	**2.9**	78.3	5.1	4.0
Consumer health care products total	15.4	**14.7**	95.3	20.1	19.0

7) Balance Sheets Data

<Assets>

(billions of yen)

	2008		Inc./
	Mar 31	**Dec 31**	(Dec.)
Current assets	306.1	**243.1**	(63.0)
Property, plant and equipment	83.4	**83.4**	(0.0)
Intangible assets	33.5	**31.4**	(2.1)
Investments and other assets	554.3	**568.4**	14.1
Non-current assets	671.1	**683.1**	12.0
Total assets	977.3	**926.2**	(51.0)

<Liabilities and Equity>

(billions of yen)

	2008		Inc./
	Mar 31	**Dec 31**	(Dec.)
Current liabilities	434.3	**115.0**	(319.3)
Long-term liabilities	71.6	**352.1**	280.6
Total liabilities	505.9	**467.1**	(38.8)
Owners' equity	461.2	**456.3**	(5.0)
Net unrealized gain and translation adjustments	9.6	**2.3**	(7.3)
Stock acquisition rights	0.6	**0.6**	0.0
Total equity	471.4	**459.1**	(12.2)
Total liabilities and equity	977.3	**926.2**	(51.0)

8. Major R&D Pipeline Candidates

1) By Development Stages

(1)New Approval

	Product Name Research Code	Indication/Mode of Action or Category	Region	Approved	Form.
	HUMIRA (D2E7)	**Rheumatoid arthritis/human anti TNF-α monoclonal antibody**	Japan	April 2008	Inj.
	IOMERON (E7337)	**Additional dosage & formulation: for use in dynamic computed tomography of the liver**	Japan	May 2008	Inj.
	ACIPHEX (E3810)	**Additional indication: short-term treatment of gastroesophageal reflux disease (GERD) in adolescents**	US	June 2008	Oral
	ALOXI (E3270)	**Additional formulation: oral formulation for the prevention of acute chemotherapy-induced nausea and vomiting (CINV)**	US	August 2008	Oral
	GASMOTIN	**Gastroprokinetic agent (generic name: mosapride citrate)**	Thai-land	September 2008	Oral
#	**ARICEPT (E2020)**	**Additional formulation: liquid formulation**	UK	October 2008	Oral
#	**BANZEL (E2080)**	**Antiepileptic agent for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (generic name: rufinamide)**	US	November 2008	Oral
#	**LUSEDRA (E2083)**	**Sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures(generic name: fospropofol)**	US	December 2008	Inj.

(2)Under Review/Preparing for Submission

	Product Name Research Code	Indication/Mode of Action or Category	Region	Submission /Target	Form.
	ARICEPT (E2020)	**Additional indication: vascular dementia**	US (EU)	November 2002 (In preparation)	Oral
	T-614	**Rheumatoid arthritis (generic name: iguratimod)**	Japan	September 2003	Oral
	E2014	**Cervical dystonia (generic name: botulinum toxin type B)**	Japan	December 2006	Inj.
	GASMOTIN	**Gastroprokinetic agent (generic name: mosapride citrate)**	Asia*[1]	May 2007	Oral
	clevudine	**Anti-chronic hepatitis B agent (generic name: clevudine)**	Asia*[1]	May 2007	Oral
	KES524	**Obesity management/central acting serotonin & noradrenaline reuptake inhibitor (generic name: sibutramine)**	Japan	November 2007	Oral
	ARICEPT (E2020)	**Additional formulation: jelly formulation**	Japan	March 2008	Oral
	GLUFAST	**Rapid-acting insulin secretagogue agent (generic name: mitiglinide)**	Asia*[1]	March 2008	Oral
	HUMIRA (D2E7)	**Additional Indication: psoriasis**	Japan	May 2008*[2]	Inj.
	DACOGEN (E7373)	**Additional dosage: five-day dosing regimen for myelodysplastic syndrome (MDS)**	US	FY2008 (target)	Inj.
	PARIET (E3810)	**Additional indication: Non-erosive gastroesophageal reflux disease**	Japan	FY2008 (target for resubmission)	Oral

#: updates from October 2008

*[1]: the countries in which applications have been filed or are under review are described in the "by therapeutic area" page. (pp. 23-24)

*[2]: As HUMIRA was approved as a new drug for the treatment of rheumatoid arthritis, the application category for psoriasis treatment was changed from NDA to an application for an additional indication. The submission timing has been changed according to the required transitional procedure.

(3)Clinical (Phase III-II/III)

	Product Name Research Code	Indication/Mode of Action or Category	Region	Phase	Submission Target	Form.
	E5564	**Severe sepsis/endotoxin antagonist (generic name: eritoran)**	US EU Japan	III III III	FY2009	Inj.
	E7389	**Anticancer agent (breast cancer)/microtubule dynamics inhibitor (generic name: eribulin)**	US EU Japan	III III II	FY2009	Inj.
	AS-3201	**Diabetic complications/aldose reductase inhibitor (generic name: ranirestat)**	US	III	FY2012	Oral
	ARICEPT (E2020)	**Additional formulation and dosage: sustained release formulation**	US EU	III III	FY2009	Oral
	ARICEPT (E2020)	**Pediatric usage (cognitive impairment associated with chemotherapy)**	US	III	FY2009	Oral
	ARICEPT (E2020)	**Pediatric usage (cognitive impairment associated with Down syndrome)**	US	III	FY2009	Oral
	ACIPHEX (E3810)	**Additional formulation: long-acting formulation**	US	III	FY2009	Oral
	SAFORIS (E6014)	**Oral mucositis/glutamine oral suspension**	US	III		Oral Suspe.
	ZONEGRAN (E2090)	**Additional indication: monotherapy for epilepsy**	EU	III	FY2010	Oral
	ZONEGRAN (E2090)	**Additional indication: pediatric epilepsy**	EU	III	FY2009	Oral
	DACOGEN (E7373)	**Additional indication: efficacy in survival benefit in myelodysplastic syndrome (MDS)**	US	III		Inj.
	DACOGEN (E7373)	**Additional indication: acute myeloid leukemia (AML)**	US	III	FY2010	Inj.
	HUMIRA (D2E7)	**Additional Indication: juvenile rheumatoid arthritis**	Japan	III	FY2011	Inj.
	HUMIRA (D2E7)	**Additional Indication: ankylosing spondylitis**	Japan	III	FY2009	Inj.
#	**HUMIRA (D2E7)**	**Additional Indication: inhibition of structural damage of joints**	Japan	III		Inj.
	E2007	**Anti-epileptic agent/AMPA receptor antagonist (generic name: perampanel)**	US EU ♯Japan	III III II	FY2012	Oral
	SEP-190	**Insomnia/$GABA_A$ receptor agonist (generic name: eszopiclone)**	Japan	III	FY2010	Oral
	clevudine	**Anti-chronic hepatitis B agent (generic name: clevudine)**	China	preparing for III		Oral
	E0302	**Amyotrophic Lateral Sclerosis (ALS) (generic name: mecobalamine)**	Japan	II/III		Inj.
	HUMIRA (D2E7)	**Additional Indication: Crohn's disease**	Japan	II/III	FY2009	Inj.
#	**HUMIRA (D2E7)**	**Additional Indication: ulcerative colitis**	Japan	II/III		Inj.
	amolimogene (E7101)	**Cervical dysplasia/therapeutic DNA vaccine**	US	II/III	FY2011	Inj.
	PARIET (E3810)	**Additional dosage: reflux esophagitis**	Japan	II/III		Oral

#: updates from October 2008

(4)Clinical (Phase II)

Product Name Research Code	Indication/Mode of Action or Category	Region	Phase	Submission Target	Form.
E2007	**Neuropathic pain/AMPA receptor antagonist (generic name: perampanel)**	US EU	II II		Oral
E2007	**Multiple sclerosis/AMPA receptor antagonist (generic name: perampanel)**	EU	II		Oral
E2007	**Migraine prophylaxis/AMPA receptor antagonist (generic name: perampanel)**	US	II		Oral
E5555	**Acute coronary syndrome/thrombin receptor antagonist**	US EU Japan	II II II	FY2012	Oral
E5555	**Atherothrombotic disease/thrombin receptor antagonist**	US EU Japan	II II II		Oral
E6201	**Psoriasis/novel MEK-1/MEKK-1 kinase inhibitor**	US	II		Topical
E7080	**Anticancer agent (thyroid cancer) /VEGF receptor tyrosine kinase inhibitor**	US	II		Oral
E7389	**Anticancer agent (non-small cell lung cancer)/ microtubule dynamics inhibitor (generic name: eribulin)**	US	II		Inj.
E7389	**Anticancer agent (prostate cancer)/microtubule dynamics inhibitor (generic name: eribulin)**	US EU	II II		Inj.
E7389	**Anticancer agent (sarcoma)/microtubule dynamics inhibitor (generic name: eribulin)**	EU	II		Inj.
E7820	**Anticancer agent (colorectal cancer)/angiogenesis inhibitor that suppresses alpha 2 integrin expression**	US	II		Oral
AKR-501	**Thrombocytopenia/thrombopoietin receptor agonist**	US	II		Oral
MORAb-003	**Anticancer agent (ovarian cancer)/humanized monoclonal antibody (generic name: farletuzumab)**	US	II		Inj.
MORAb-009	**Anticancer agent (pancreatic cancer)/ monoclonal antibody**	US	II		Inj.
ARICEPT (E2020)	**Additional indication: Lewy body dementia**	Japan	II		Oral
irofulven (E7850)	**Anticancer agent (prostate and other cancer) /DNA synthesis inhibitor**	US	II		Inj.
E7210 (suspended)	**Ultrasonic contrast medium**	Japan	II		Inj.

2)By Therapeutic Areas

(1)Neurology

Product Name Research Code	Description	Development Status
ARICEPT (E2020)	Currently approved acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.	**Additional Indications** Vascular dementia: under review (US) Pediatric usage: Phase III (US) Lewy body dementia: Phase II (Japan) **Additional formulations** Liquid: approved (UK) Jelly: under review (Japan) Sustained-release formulation: Phase III (EU/US)
E2007	The generic name is perampanel. A selective antagonist of the AMPA-type glutamate receptor, it could potentially be developed for treating a variety of neurodegenerative disorders.	Epilepsy: Phase III (EU/US), Phase II (Japan) Neuropathic pain: Phase II (EU/US) Migraine prophylaxis: Phase II (US) Multiple sclerosis: Phase II (EU)
AS-3201	The generic name is ranirestat. It is being investigated as a potential treatment for diabetic complications through inhibition of aldose reductase.	Diabetic neuropathy: Phase III (US)
BANZEL (E2080)	The agent has been approved in Europe for adjunctive therapy for Lennox-Gastaut syndrome (LGS) with the brand name of INOVELON . In the U.S., the agent received approval by the FDA with the brand name of BANZEL.	Adjunctive therapy in LGS: approved (US)
ZONEGRAN (E2090)	The generic name is zonisamide. It is believed to have broad anti-epileptic action and to be well-tolerated. Currently indicated as adjunctive therapy for partial seizures in adults with epilepsy.	**Additional indications** Monotherapy: Phase III (EU) Pediatric indication: Phase III (EU)
E0302	Mecobalamine is widely used for the treatment of peripheral neuropathy in Japan. A Phase II/III study for amyotrophic lateral sclerosis (ALS) is ongoing.	Amyotrophic lateral sclerosis: Phase II/III (Japan)
E2014	Botulinum toxin acts on cholinergic nerve ending synapses and inhibits the release of acetylcholine to relax muscles.	Cervical dystonia: under review (Japan)
SEP-190	Eszopiclone is a non-benzodiazepine type allosteric $GABA_A$ receptor agonist that may help patients with transient insomnia as well as insomnia in the elderly.	Insomnia: Phase III (Japan)

(2)Oncology and Supportive Care

Product Name Research Code	Description	Development Status
E7389	The generic name is eribulin. It is a synthetic analog of halichondrin B derived from a marine sponge. It prevents tumor development by inhibiting cell division through inhibition of microtubule dynamics. Proof of concept (POC) was achieved in breast cancer.	Breast cancer: Phase III (EU/US), Phase II (Japan) NSCLC: Phase II (US) Prostate cancer: Phase II (EU/US) Sarcoma: Phase II (EU)
E7820	The compound is an angiogenesis inhibitor that suppresses alpha 2 integrin	Colorectal cancer: Phase II (US)
E7080	The compound is a VEGF receptor tyrosine kinase inhibitor.	Thyroid cancer: Phase II (US)
MORAb-003	The compound is a humanized IgG1 MAb to folate receptor alpha.	Ovarian cancer: Phase II (US)
MORAb-009	The compound is an IgG1 MAb that targets mesothelin.	Pancreatic cancer: Phase II (US)
DACOGEN (E7373)	The generic name is decitabine. It induces cell differentiation activity through inhibition of DNA methylation. It is currently approved for myelodysplastic syndrome (MDS) in the United States.	**Additional indications** Acute myeloid leukemia: Phase III (US) Efficacy in survival benefit in MDS patients: Phase III (US) **Additional dosage**: five-day dosing regimen for MDS: submission in preparation (US)
irofulven (E7850)	This compound is believed to show an anticancer effect by its DNA synthesis inhibiting action.	Prostate cancer: Phase II (US)
ALOXI (E3270)	A serotonin (5-HT3) receptor antagonist, the agent is approved for chemotherapy-induced nausea and vomiting (CINV) as well as postoperative nausea and vomiting (PONV) in the United States.	**Additional formulation** Oral formulation (prevention of acute CINV) : approved (US)
AKR-501	The agent is an orally available thrombopoietin receptor agonist.	Idiopathic thrombocytopenic purpura: Phase II (US)
amolimogene (E7101)	The agent is a therapeutic DNA vaccine that has shown activity against human papillomavirus.	Cervical dysplasia: Phase II/III (US)
LUSEDRA (E2083)	The generic name is fospropofol. It is a water-soluble prodrug of propofol. Received approval in the U.S.	Sedation in adult patients undergoing diagnostic or therapeutic procedures: approved (US)
SAFORIS (E6014)	The agent is a topical, oral suspension of glutamine to protect oral mucosa from the damaging effects of chemotherapy.	Oral mucositis: Phase III (US)

(3)Vascular and Immunological Reaction

Product Name Research Code	Description	Development Status
HUMIRA (D2E7)	The generic name is adalimumab. It is a human anti-TNF-α monoclonal antibody. In Japan, approval was obtained for the indication of rheumatoid arthritis.	Rheumatoid arthritis: approved (Japan) **Additional indication** Psoriasis: under review (Japan) Juvenile rheumatoid arthritis: Phase III (Japan) Ankylosing spondylitis: Phase III (Japan) Inhibition of structural damage of joints: Phase III (Japan) Crohn's disease: Phase II/III (Japan) Ulcerative colitis: Phase II/III (Japan)
E5564	The generic name is eritoran. The compound has demonstrated endotoxin antagonist activity. It showed expected efficacy and tolerability in a Phase II POC study for severe sepsis, which is caused by endotoxin from various types of gram-negative bacteria.	Severe sepsis: Phase III (Global Development Program)
E5555	The compound inhibits platelet aggregation and smooth-muscle proliferation based on thrombin receptor antagonistic action.	Acute coronary syndrome: Phase II (Japan/US/EU) Atherothrombotic disease: Phase II
E6201	The agent is a novel MEK-1/MEKK-1kinase inhibitor.	Psoriasis: Phase II (US)
T-614	The agent suppresses inflammatory cytokine production, lymphocyte proliferation and immunoglobulin production.	Rheumatoid arthritis: under review (Japan)

(4)Gastrointestinal Disorders

Product Name Research Code	Description	Development Status
ACIPHEX/ PARIET (E3810)	The agent is a proton pump inhibitor and is approved for duodenal ulcers, reflux esophagitis and eradication of *H. pylori* infection, etc. In addition, short-term treatment of GERD in adolescents was approved.	**Additional indications** Gastro-esophageal reflux disease (GERD) in adolescents: approved (US) Non-erosive GERD: in preparation for resubmission (Japan) **Additional dosage** Reflux esophagitis: Phase II/III (Japan) **Additional formulation** Long-acting formulation: Phase III (US)
GASMOTIN	The generic name is mosapride citrate. It is a selective serotonin 5-HT_4 receptor agonist that has gastroprokinetic and gastric evacuation effects by enhancing acetylcholine release.	Gastroprokinetic agent: approved (Thailand), under review (Malaysia/Indonesia/the Philippines), prepared for submission (six Asian countries including some ASEAN members)

(5)Other Therapeutic Areas

Product Name Research Code	Description	Development Status
IOMERON (E7337)	The agent received approval as a non-ionic X-ray contrast medium in computed tomography in Japan. Additional dosage & formulation for usage in dynamic computed tomography of the liver was approved.	**Additional indication and formulation** Dynamic CT of the liver: approved (Japan)
KES524	The generic name is sibutramine. It inhibits the reuptake of the cerebral neurotransmitters serotonin and noradrenaline. By enhancing the feeling of satiety and increasing energy consumption, it is expected to promote the loss of body weight.	Obesity management: under review (Japan)
clevudine	The compound is a DNA polymerase inhibitor that shows efficacy as an antivirus agent for chronic hepatitis caused by hepatitis B virus.	Chronic hepatitis B: under review (Malaysia/Thailand/Indonesia/the Philippines /India), submission in preparation (three Asian countries including some ASEAN member countries), in preparation for Phase III (China)
GLUFAST	The generic name is mitiglinide. It is an agonist for sulfonylurea receptors in pancreatic beta cells and reduces blood glucose levels by accelerating insulin release.	Diabetes: under review (Malaysia/Thailand/the Philippines/Indonesia/Singapore), submission in preparation (five ASEAN member countries)
E7210	The compound is a contrast medium for ultrasound based on the principle of ultrasound reflection by micro bubbles.	Suspended (Japan)

9. Major Events

Date	Description
April 2008	・ Eisai received a notification from the U.S. FDA that it may proceed with the clinical study for E2012, a potential next generation Alzheimer's disease treatment <announced on April 3>
	・ Announced the status of the E2007 (AMPA-type glutamate receptor antagonist) development program <announced on April 11>
	・ HUMIRA, a fully-human monoclonal anti-TNF-α antibody received approval in Japan for the treatment of rheumatoid arthritis <announced on April 16>
	・ European Commission granted orphan drug status to anticancer agents MORAb-003 and MORAb-009 <announced on April 16>
	・ Signed an agreement with Sanko Junyaku Co., Ltd., Roche Diagnostics K.K., and Nihon Kohden Corp. concerning the sales of COAGUCHEK XS series for simple and quick PT-INR monitoring for warfarin-treated patients <announced on April 17>
	・ Announced a notice of revised business forecast for the fiscal year ended March 31, 2008, as a result of the acquisition of MGI PHARMA, INC. <announced on April 21>
	・ Introduced CHOCOLA BB ROYAL 2, vitamin B_2 drink for extreme fatigue in Japan (launched on May 12) <announced on April 24>
	・ Launched liver disease/allergic disease treatment STRONGER NEO-MINOPHAGEN C in Japan
May	・ Gained a favorable ruling by Court of Appeal in the U.K. finding the National Institute for Health and Clinical Excellence (NICE) process for developing guidance on anti-dementia medicines was unfair <announced on May 1>
	・ Established a new subsidiary for marketing support and maintenance of pharmaceutical machinery in China <announced on May 7>
	・ The U.S. FDA advisory committee voted in favor of approval of fospropofol disodium injection <announced on May 8>
	・ The U.K. Court of Appeal makes decision following ruling with regards to the NICE (National Institute for Health and Clinical Excellence) process on anti-dementia medicines <announced on May 9>
	・ Signed an agreement with Lion Corporation regarding exclusive authorization for sales in Japan for an ethical drug of BUFFERIN tablets <announced on May 12>
	・ Announced the notice on new stock issuance in the form of stock options <announced on May 14>
	・ Presented 16 papers accepted for ASCO Annual Meeting reporting the latest results from oncology research <announced on May 16>
	・ Presented a study report of E7389 in heavily pretreated patients with advanced breast cancer in ASCO Annual Meeting <announced on May 16>
	・ Non-ionic contrast media, IOMERON 350 and IOMERON 350 syringe, received approval for use in dynamic CT of the liver <announced on May 22>
	・ Terminated a marketing alliance of BREATHE RIGHT nasal strips with GlaxoSmithKline K.K. <announced on May 29>
	・ Announced a notice with respect to issuance of Unsecured Straight Bonds <announced on May 29>
June	・ Launched HUMIRA subcutaneous injection 40mg Syringe 0.8mL (fully-human monoclonal anti-TNFα antibody) for the treatment of rheumatoid arthritis in Japan. <announced on June 17>
	・ Announced the transfer of shares in subsidiary Clinical Supply Co., Ltd. <announced on June 19>
	・ Announced a notice on allocation of stock options (stock acquisition rights) <announced on June 20>
	・ Clinical sites for MORAb-009 Phase II study were expanded to the European Union (EU)
	・ U.S. subsidiary Morphotek, Inc. signed a license agreement with the National Cancer Institute (NCI) for the development of therapeutic antibodies for use in the treatment of prostate cancer

Date	Description
July	・ Proton pump inhibitor ACIPHEX 20 mg received approval for the short-term treatment of GERD in adolescents in United States <announced on July 1>
	・ Announced the preliminary efficacy update on EORTC Phase III Trial of DACOGEN versus supportive care in patients with myelodysplastic syndromes (MDS) <announced on July 1>
	・ Issued a notice on determination of details of stock options (stock acquisition rights) to be allocated <announced on July 7>
	・ ALOXI injection 0.075 mg became available for prevention of postoperative nausea and vomiting (PONV) in the U.S. <announced on July 9>
	・ Antiosteoporotic drug ACTONEL 17.5 mg tablets received approval for additional indication in patients with Paget's disease of bone, and a new package became available <announced on July 16>
	・ U.S. Federal Circuit Court of Appeals fully upheld Eisai's favorable ruling in ACIPHEX patent infringement lawsuit <announced on July 22>
	・ Eisai received Action Letter on fospropofol disodium injection for sedation in diagnostic or therapeutic procedures which outlines pathway to potential approval <announced on July 26>
	・ Eisai China Inc. signed a license agreement with a Chinese subsidiary of *STADA Arzneimittel* (Germany) AG Health Vision Enterprise Ltd. (Hong Kong) for the sales of the treatment for diabetic neuropathic pain α-LIPON 300 STADA in China <announced on July 30>
	・ Announced a determination to continue "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" <announced on July 31>
	・ U.S. subsidiary Morphotek, Inc. signed an agreement with Pivotal BioSciences, Inc. (U.S.) for the evaluation of LEC (Liver-Expression Chemokine) platform technology
August	・ Signed an exclusive license agreement with SymBio Pharmaceuticals Limited for the co-development and commercialization of bendamustine hydrochloride in Japan <announced on August 18>
	・ ALOXI Capsules, anti-emetogenic agent for the prevention of chemotherapy-induced nausea and vomiting (CINV), received marketing approval in the U.S. <announced on August 24>
September	・ Introduced HOTMIN in Japan for improving peripheral blood circulation to relieve symptoms of coldness in extremities and stiff shoulders (launched on September 16) <announced on September 3>
October	・ Introduced CHOCOLA BB DRINK BIT, a new pharmaceutical drink for acne and skin care in Japan (launched on October 15) <announced on October 8>
	・ The U.S. FDA approved an efficacy supplemental biologics license application (sBLA) for ONTAK for the treatment of patients with cutanous T-cell lymphoma (CTCL) (conversion of accelerated approval to full approval) <announced on October 16>
	・ Received an announcement from the U.K. House of Lords that they have refused the NICE's application for leave to appeal against the Court of Appeal verdict <announced on October 29>
	・ Launched liver disease/allergic disease treatment GLYCYRON in Japan
	・ Liquid formulation of ARICEPT, the Alzheimer's disease treatment, was approved in the U.K.
November	・ Completed alliance agreement with TorreyPines Therapeutics, Inc. (U.S.) for genetic research programs to discover genes associated with late onset Alzheimer's disease, and signed a new agreement for Eisai to purchase research assets <announced on November 11>
	・ Antiepileptic agent BANZEL was approved by the U.S. FDA for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) <announced on November 17>
	・ U.S. subsidiary Morphotek, Inc. signed a sponsored research agreement with the University of Pennsylvania to fund research for the development of therapeutic antibody candidates
	・ U.S. subsidiary Morphotek, Inc. signed an evaluation agreement with the University Hospital Heidelberg (Germany) and its Technology Transfer Office to advance the company's efforts in the discovery and development of therapeutic antibodies in oncology
December	・ The U.S. FDA approved LUSEDRA Injection, an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures <Announced on December 15>
	・ Launched liver disease/allergic disease treatment STRONGER NEO-MINOPHAGEN C in Taiwan
January 2009	・ Launched antiepileptic agent BANZEL in the U.S.